<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005068.pub2" GROUP_ID="SKIN" ID="679503111311301673" MERGED_FROM="" MODIFIED="2015-08-05 10:55:02 +0100" MODIFIED_BY="Helen Scott" REVIEW_NO="#89" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2015-08-05 10:55:02 +0100" MODIFIED_BY="Helen Scott">
<TITLE>Interventions for pityriasis rosea</TITLE>
<CONTACT MODIFIED="2015-08-05 10:55:02 +0100" MODIFIED_BY="Helen Scott"><PERSON ID="D3513AC082E26AA20080535FE92C6BC7" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Antonio</FIRST_NAME><MIDDLE_INITIALS>AT</MIDDLE_INITIALS><LAST_NAME>Chuh</LAST_NAME><POSITION>Part time Associate Professor</POSITION><EMAIL_1>antonio.chuh@yahoo.com.hk</EMAIL_1><EMAIL_2>achuh@iohk.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Community and Family Medicine</DEPARTMENT><ORGANISATION>The Chinese University of Hong Kong</ORGANISATION><ADDRESS_1>Shop B5, Ning Yeung Terrace</ADDRESS_1><ADDRESS_2>78 Bonham Road, Ground Floor, The Mid-Levels,</ADDRESS_2><CITY>Hong Kong</CITY><COUNTRY CODE="HK">Hong Kong</COUNTRY><PHONE_1>+852 25590420</PHONE_1><PHONE_2>+852 25174081</PHONE_2><FAX_1>+852 23703330</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-08-05 10:55:02 +0100" MODIFIED_BY="Helen Scott"><PERSON ID="D3513AC082E26AA20080535FE92C6BC7" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Antonio</FIRST_NAME><MIDDLE_INITIALS>AT</MIDDLE_INITIALS><LAST_NAME>Chuh</LAST_NAME><POSITION>Part time Associate Professor</POSITION><EMAIL_1>antonio.chuh@yahoo.com.hk</EMAIL_1><EMAIL_2>achuh@iohk.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Community and Family Medicine</DEPARTMENT><ORGANISATION>The Chinese University of Hong Kong</ORGANISATION><ADDRESS_1>Shop B5, Ning Yeung Terrace</ADDRESS_1><ADDRESS_2>78 Bonham Road, Ground Floor, The Mid-Levels,</ADDRESS_2><CITY>Hong Kong</CITY><COUNTRY CODE="HK">Hong Kong</COUNTRY><PHONE_1>+852 25590420</PHONE_1><PHONE_2>+852 25174081</PHONE_2><FAX_1>+852 23703330</FAX_1></ADDRESS></PERSON><PERSON ID="D3513D9F82E26AA20080535FE9C768F8" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Belen</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Dofitas</LAST_NAME><POSITION>Assistant Chief for Research and Community Dermatology</POSITION><EMAIL_1>belendofitas@gmail.com</EMAIL_1><EMAIL_2>belendofitas@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Dermatology</DEPARTMENT><ORGANISATION>St. Luke's Medical Center</ORGANISATION><ADDRESS_1>12th floor, North Tower, Cathedral Heights Bldg.Complex</ADDRESS_1><ADDRESS_2>279 E. Rodriguez Sr. Boulevard</ADDRESS_2><CITY>Quezon City</CITY><ZIP>1112</ZIP><REGION>Metro Manila</REGION><COUNTRY CODE="PH">Philippines</COUNTRY><PHONE_1>+632 9314568</PHONE_1><PHONE_2>+632 5265027</PHONE_2><FAX_1>+632 5265027</FAX_1></ADDRESS></PERSON><PERSON ID="D3513BBA82E26AA20080535F4AE581AE" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gabriela</FIRST_NAME><LAST_NAME>Comisel</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Primary Family Physician</POSITION><EMAIL_1>comiselgabriela@hotmail.com</EMAIL_1><EMAIL_2>bratugabi@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Famiy Medical Office</DEPARTMENT><ORGANISATION>Romanian Family Doctors Collegium</ORGANISATION><ADDRESS_1>Str. C. Brancusi</ADDRESS_1><ADDRESS_2>Bl, A2, Sc. 3, Ap. 7</ADDRESS_2><CITY>Craiova</CITY><REGION>Dolj</REGION><COUNTRY CODE="RO">Romania</COUNTRY><PHONE_1>+402 51592020</PHONE_1><PHONE_2>+402 51581790</PHONE_2><FAX_1>+40251592020</FAX_1></ADDRESS></PERSON><PERSON ID="14522" ROLE="AUTHOR"><FIRST_NAME>Ludovic</FIRST_NAME><LAST_NAME>Reveiz</LAST_NAME><SUFFIX>MD, MSc, PhD</SUFFIX><EMAIL_1>mmreveiz@hotmail.com</EMAIL_1><EMAIL_2>reveizl@paho.org</EMAIL_2><ADDRESS><DEPARTMENT>Free time independent Cochrane reviewer</DEPARTMENT><ORGANISATION/><CITY>Potomac</CITY><REGION>MD</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="D3514EA682E26AA20080535F1F9F86C1" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Vidya</FIRST_NAME><LAST_NAME>Sharma</LAST_NAME><POSITION>Professor of Pediatrics</POSITION><EMAIL_1>vsharma@cmh.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>The Children's Mercy Hospital and Clinics</ORGANISATION><ADDRESS_1>2401 Giham Road</ADDRESS_1><CITY>Kansas City</CITY><ZIP>MO 64108</ZIP><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+816 2343684</PHONE_1><FAX_1>+816 9836838</FAX_1></ADDRESS></PERSON><PERSON ID="14935" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sarah</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Garner</LAST_NAME><SUFFIX>BPharm PhD MRPharms</SUFFIX><POSITION>Associate Director</POSITION><EMAIL_1>Sarah.Garner@nice.org.uk</EMAIL_1><EMAIL_2>SGarner@nice.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Science Policy and Research</DEPARTMENT><ORGANISATION>National Institute for Health and Care Excellence (NICE)</ORGANISATION><ADDRESS_1>MidCity Place</ADDRESS_1><ADDRESS_2>71 High Holborn</ADDRESS_2><CITY>London</CITY><ZIP>WC1V 6NA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+447748147742</PHONE_1></ADDRESS></PERSON><PERSON ID="FE004C7082E26AA201D6C275115303C7" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Fergus</FIRST_NAME><MIDDLE_INITIALS>KM</MIDDLE_INITIALS><LAST_NAME>Chu</LAST_NAME><POSITION>Solicitor</POSITION><EMAIL_1>qqs@netvigator.com</EMAIL_1><ADDRESS><ORGANISATION>Messrs. Gary Lau &amp; Partners</ORGANISATION><ADDRESS_1>Unit 401, Golden Centre</ADDRESS_1><ADDRESS_2>188 Des Voeux Road Central</ADDRESS_2><CITY>Hong Kong</CITY><COUNTRY CODE="HK">Hong Kong</COUNTRY><PHONE_1>852-25443228</PHONE_1><FAX_1>852-25449900</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-07-24 12:43:27 +0100" MODIFIED_BY="Cathy Bennett">
<UP_TO_DATE>
<DATE DAY="21" MONTH="2" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="2" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="5" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2015-08-05 10:50:48 +0100" MODIFIED_BY="Helen Scott">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-08-05 10:50:48 +0100" MODIFIED_BY="Helen Scott">
<DATE DAY="5" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>Author information (affiliation) updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-08-05 10:49:59 +0100" MODIFIED_BY="Helen Scott">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-08-05 10:49:59 +0100" MODIFIED_BY="Helen Scott">
<DATE DAY="6" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-24 12:44:11 +0100" MODIFIED_BY="Cathy Bennett">
<DATE DAY="2" MONTH="8" YEAR="2007"/>
<DESCRIPTION>
<P>Minor update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="21" MONTH="2" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-06 09:35:37 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-07-24 13:26:54 +0100" MODIFIED_BY="Cathy Bennett" NOTES="&lt;p&gt;Have created plain language summary, author please check and revise.&lt;/p&gt;" NOTES_MODIFIED="2008-07-24 13:26:54 +0100" NOTES_MODIFIED_BY="Cathy Bennett">
<TITLE MODIFIED="2008-07-24 13:26:32 +0100" MODIFIED_BY="Cathy Bennett">Interventions for pityriasis rosea, skin rash of unknown cause</TITLE>
<SUMMARY_BODY MODIFIED="2008-07-24 12:45:27 +0100" MODIFIED_BY="Cathy Bennett">
<P>Pityriasis rosea is a scaly rash that mostly affects young adults. It is relatively common and affects about 170 out of every 100,000 people in the community each year. The first sign is a patch of scales, usually on the trunk. A generalised eruption then follows and all lesions disappear within 2 to 12 weeks. This review is important because about 50% of people with pityriasis rosea experience moderate to severe itch. It is not known whether the current treatments, which include tablets, creams, and ultra-violet radiation, are useful and whether the benefits outweigh the risk of adverse effects.</P>
<P>We found three randomised controlled trials involving 148 participants. One small poor quality trial compared liquorice root with an anaesthetic injected intravenously (23 people), a fair quality trial compared an antihistamine with a steroid taken orally (85 people), and a good quality trial that compared an antibiotic with placebo tablets (40 people).</P>
<P>The poor quality trial found no significant difference between liquorice root and anaesthetic for resolving symptoms or rash. The fair quality trial found no significant difference in itch resolution between the antihistamine and the steroid. However the antihistamine and the steroid on their own were both found to be better at clearing rash than a combination of antihistamine and steroid. The small good quality trial found that the oral antibiotic erythromycin was better than placebo in improving the rash and decreasing the amount of itching.</P>
<P>No serious adverse effects were reported for any intervention. Two out of 17 people on oral erythromycin and 1 out of 17 people on oral placebo reported minor gastrointestinal upset.</P>
<P>We conclude that there is inadequate evidence of efficacy for most treatments but oral erythromycin may be effective in treating the rash and relieving the itch.</P>
<P>Limitations of this review include the small number of trials identified, the small number of participants involved, the inadequate methodology of two of the studies, and finding only one small study that reported the clinical benefits of oral erythromycin.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Pityriasis rosea is a scaly rash that mainly affects young adults. It can be very itchy but most people recover within 2 to 12 weeks. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of interventions for pityriasis rosea.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Skin Group Specialised Register (December 2004), the Cochrane Central Register of Controlled Clinical Trials in <I>The Cochrane Library</I> (Issue 4, 2004), MEDLINE (1966 to January 2005), EMBASE (1976 to January 2005), LILACS (1982 to January 2005), BIOSIS Preview (1980 to June 2002), and ongoing trials databases. We scanned bibliographies of published studies, abstracts from dermatology conference proceedings, corresponded with trialists and contacted the pharmaceutical industry. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials evaluating interventions for pityriasis rosea.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently assessed trial quality and extracted data. We contacted study authors to retrieve missing data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Three trials involving 148 people were included. One poor quality trial (23 people), compared intravenous glycyrrhizin and intravenous procaine. It found no significant difference between the two interventions for treating symptoms and rash.</P>
<P>One fair quality trial (85 people), compared the oral antihistamine dexchlorpheniramine (4 mg), the oral steroid betamethasone (500 mcg), and a combination of betamethasone (250 mcg) and dexchlorpheniramine (2 mg). It found no significant difference in itch resolution at two weeks, as rated by the participants, between dexchlorpheniramine and betamethasone, and the combination of dexchlorpheniramine and betamethasone. However, both dexchlorpheniramine and betamethasone alone seem to be better at clearing rash than the combination of dexchlorpheniramine and betamethasone. These interventions were not compared with placebo. </P>
<P>The small good quality trial (40 people) that compared oral erythromycin and placebo found that erythromycin was more effective than placebo in terms of rash improvement, as rated by the trialists, after two weeks (RR 13.00; 95% CI 1.91 to 88.64). It was also more effective in decreasing the itch score (difference of 3.95 points, 95% CI 3.37 to 4.53).<BR/> <BR/>No serious adverse effects were reported for the interventions. Two out of 17 people on oral erythromycin and 1 out of 17 on placebo reported minor gastrointestinal upset. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>We found inadequate evidence for efficacy for most treatments for pityriasis rosea. Oral erythromycin may be effective in treating the rash and decreasing the itch. However, this result should be treated with caution since it comes from only one small RCT. More research is necessary to evaluate the efficacy of erythromycin and other treatments. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-06 09:35:37 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-08-06 09:02:10 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2008-08-06 09:02:10 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Description and epidemiology</HEADING>
<P>Pityriasis rosea (PR) is a skin disorder that describes a sudden appearance of discrete plaques (patches) of skin rash in a distinctive pattern over the body and limbs. 'Pityriasis' (meaning bran-like), indicates that there are scales in the skin lesions (<LINK REF="REF-Percival-1932" TYPE="REFERENCE">Percival 1932</LINK>). 'Rosea' means rose-like and describes the typical colour of the rash (<LINK REF="REF-Percival-1932" TYPE="REFERENCE">Percival 1932</LINK>), although the colour varies to a wide extent in different races (<LINK REF="REF-Ahmed-1986" TYPE="REFERENCE">Ahmed 1986</LINK>).</P>
<P>A characteristic of PR is the apparently 'programmed' course of events. Many people will discover one plaque, usually on the trunk, several days before the generalised eruption. This initial lesion is known as the herald patch (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). However, the herald patch may not be identifiable in many people and thus its absence does not necessarily exclude a diagnosis of PR.</P>
<P>The subsequent generalised eruption is known as the secondary eruption. It usually occurs on the trunk and extends to the upper arms and upper thighs. In some people, the forearms and legs can be involved. Involvement of the face is rare but has been reported (<LINK REF="REF-Klauder-1924" TYPE="REFERENCE">Klauder 1924</LINK>; <LINK REF="REF-Vollum-1973" TYPE="REFERENCE">Vollum 1973</LINK>). The palms of the hands and soles of the feet are usually unaffected.</P>
<P>More plaques will keep on appearing in the first two to six weeks. All lesions will then disappear spontaneously without treatment. The entire disease duration is usually between 2 and 12 weeks, but may last for as long as 5 months (<LINK REF="REF-Nelson-2000" TYPE="REFERENCE">Nelson 2000</LINK>). After recovery, some darkening or lightening of the affected skin (but not scarring) might however remain for months (<LINK REF="REF-Truhan-1984" TYPE="REFERENCE">Truhan 1984</LINK>).</P>
<P>The rash is not painful, but about 50% of people with PR will experience itching of moderate to severe intensity (<LINK REF="REF-Bjornberg-1962" TYPE="REFERENCE">Bjornberg 1962</LINK>) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Most people who have had an episode of PR will not have another attack throughout their lifetime (<LINK REF="REF-Bjornberg-1962" TYPE="REFERENCE">Bjornberg 1962</LINK>; <LINK REF="REF-Chuang-1982" TYPE="REFERENCE">Chuang 1982</LINK>).</P>
<P>Pityriasis rosea is a relatively common condition. We analysed data from 9 studies (<LINK REF="REF-Vollum-1973" TYPE="REFERENCE">Vollum 1973</LINK>; <LINK REF="REF-Jacyk-1980" TYPE="REFERENCE">Jacyk 1980</LINK>; <LINK REF="REF-de-Souza-1984" TYPE="REFERENCE">de Souza 1984</LINK>; <LINK REF="REF-Ahmed-1986" TYPE="REFERENCE">Ahmed 1986</LINK>; <LINK REF="REF-Olumide-1987" TYPE="REFERENCE">Olumide 1987</LINK>; <LINK REF="REF-Cheong-1989" TYPE="REFERENCE">Cheong 1989</LINK>; <LINK REF="REF-Harman-1998" TYPE="REFERENCE">Harman 1998</LINK>; <LINK REF="REF-Nanda-1999" TYPE="REFERENCE">Nanda 1999</LINK>; <LINK REF="REF-Tay-1999" TYPE="REFERENCE">Tay 1999</LINK>) and found that out of every 1000 people seen by dermatologists, about 7 are diagnosed with PR. One study (<LINK REF="REF-Chuang-1982" TYPE="REFERENCE">Chuang 1982</LINK>) reported that for every 100,000 people in the community, about 170 will have PR in any one year.</P>
<P>Most people with PR are between 10 and 35 years of age (<LINK REF="REF-Truhan-1984" TYPE="REFERENCE">Truhan 1984</LINK>). Girls and women are more likely to have PR; the overall male to female ratio is about 1:1.4. The data on seasonal variation in the occurrence of PR is conflicting. However, it is known that cases of PR tend to occur in clusters (<LINK REF="REF-Messenger-1982" TYPE="REFERENCE">Messenger 1982</LINK>; <LINK REF="REF-Chuh-2003a" TYPE="REFERENCE">Chuh 2003a</LINK>, <LINK REF="REF-Chuh-2005c" TYPE="REFERENCE">Chuh 2005c</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Terminology</HEADING>
<P>PR is also known by the following names: pityriasis rosea of Gibert, pityriasis rosea of Vidal, pityriasis circinata et marginata, and pityriasis maculata et circinata (<LINK REF="REF-Percival-1932" TYPE="REFERENCE">Percival 1932</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Causes</HEADING>
<P>The cause of PR is unknown. Three major facts suggest that PR is caused by an infectious agent. The first is that the disease course, as mentioned above, is 'programmed'. This programmed course of events is similar to the course of some viral rashes such as measles or chicken pox. The second is that most people who have suffered from the eruption will not have another attack throughout their lifetime. This suggests that PR is caused by an infectious agent. If a person has had an attack, they will develop immunity against the infectious agent, and therefore be free from further attacks. The third fact is that some cases of PR tend to cluster, suggesting that it is potentially infectious.</P>
<P>Researchers have searched for the infectious agent for generations to no avail. Recently the focus has been on the roles of two viruses - human herpesvirus 6 and human herpesvirus 7. Different investigators have however reported conflicting results. There are positive reports (<LINK REF="REF-Drago-1997a" TYPE="REFERENCE">Drago 1997a</LINK>; <LINK REF="REF-Drago-1997b" TYPE="REFERENCE">Drago 1997b</LINK>; <LINK REF="REF-Watanabe-1999" TYPE="REFERENCE">Watanabe 1999</LINK>; <LINK REF="REF-Watanabe-2002" TYPE="REFERENCE">Watanabe 2002</LINK>, <LINK REF="REF-Vag-2003" TYPE="REFERENCE">Vag 2003</LINK>; <LINK REF="REF-Vag-2004" TYPE="REFERENCE">Vag 2004</LINK>; <LINK REF="REF-Broccolo-2005" TYPE="REFERENCE">Broccolo 2005</LINK>) supporting the role of one or both of these viruses as well as many negative reports (<LINK REF="REF-Kempf-1999" TYPE="REFERENCE">Kempf 1999</LINK>; <LINK REF="REF-Yasukawa-1999" TYPE="REFERENCE">Yasukawa 1999</LINK>; <LINK REF="REF-Yoshida-1999" TYPE="REFERENCE">Yoshida 1999</LINK>; <LINK REF="REF-Kosuge-2000" TYPE="REFERENCE">Kosuge 2000</LINK>; <LINK REF="REF-Offidani-2000" TYPE="REFERENCE">Offidani 2000</LINK>; <LINK REF="REF-Chuh-2001" TYPE="REFERENCE">Chuh 2001</LINK>; <LINK REF="REF-Wong-2001" TYPE="REFERENCE">Wong 2001</LINK>; <LINK REF="REF-Karabulut-2002" TYPE="REFERENCE">Karabulut 2002</LINK>; <LINK REF="REF-Yildirim-2004" TYPE="REFERENCE">Yildirim 2004</LINK>). The role of these viruses in causing PR is controversial at the present. PR has recently been reported not to be associated with human herpesvirus 8 infection (<LINK REF="REF-Chuh-2006" TYPE="REFERENCE">Chuh 2006</LINK>).</P>
<P>Some drugs produce a skin rash as a side-effect, which can resemble pityriasis rosea. However, these rashes are different in nature from PR (<LINK REF="REF-Chuh-2003b" TYPE="REFERENCE">Chuh 2003b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Impact</HEADING>
<P>About 50% of all people with PR have itching of moderate to severe intensity (<LINK REF="REF-Bjornberg-1962" TYPE="REFERENCE">Bjornberg 1962</LINK>). The quality of life of people with PR is significantly affected (<LINK REF="REF-Chuh-2003c" TYPE="REFERENCE">Chuh 2003c</LINK>; <LINK REF="REF-Chuh-2005a" TYPE="REFERENCE">Chuh 2005a</LINK>). Parents of children with PR also have significant anxieties about the cause, nature, and possible infectivity of the eruption (<LINK REF="REF-Chuh-2003c" TYPE="REFERENCE">Chuh 2003c</LINK>).</P>
<P>Many people with PR are likely to consult a primary care physician, but primary care physicians have been reported significantly to under diagnose this disease (<LINK REF="REF-Pariser-1987" TYPE="REFERENCE">Pariser 1987</LINK>). If people consult a primary care physician and a precise diagnosis of PR is not given, they can become anxious about the nature of the eruption and its prognosis.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2008-07-24 13:28:20 +0100" MODIFIED_BY="Cathy Bennett">
<P>Currently both topical and systemic treatments are used to treat pityriasis rosea. Topical treatments mainly comprise emollients and topical corticosteroids. Systemic treatments include medications for symptomatic control such as oral antihistamines, sunlight and artificial ultraviolet radiation (usually as narrow-band ultraviolet-B), systemic corticosteroids, and oral antibiotics. The use of antiviral agents, like acyclovir, has also been reported (<LINK REF="REF-Castanedo-2003" TYPE="REFERENCE">Castanedo 2003</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2008-07-24 13:28:26 +0100" MODIFIED_BY="Cathy Bennett">
<P>The current use of some treatments for pityriasis rosea is based on anecdotal experience only. Conflicting results have also been reported for some treatments. For example, oral corticosteroids have been reported to be of benefit to people with very extensive PR (<LINK REF="REF-Tay-1999" TYPE="REFERENCE">Tay 1999</LINK>). On the other hand, there are reports of PR getting worse when treated with systemic corticosteroids (<LINK REF="REF-Leonforte-1981" TYPE="REFERENCE">Leonforte 1981</LINK>).</P>
<P>The use of some treatments may also be related to inadequate understanding of the present controversies about the cause of PR. For example, the association of human herpesvirus 7 infection with PR is still controversial. Even if human herpesvirus 7 infection is the true cause of pityriasis rosea, acyclovir would be a poor choice for antiviral therapy since it has little to no action against human herpesvirus 7 in laboratory conditions (<LINK REF="REF-Zhang-1999" TYPE="REFERENCE">Zhang 1999</LINK>). Its action depends on the enzyme thymidine kinase and human herpesvirus 7 does not possess the gene coding for this enzyme.</P>
<P>Pityriasis rosea is an essentially a self limiting disease and the rash mostly disappears at 2 to 12 weeks, with or without treatment. The benefits associated with the use of any active intervention should therefore outweigh any potential adverse effects. Adverse effects may be short-term (such as stomach upsets caused by antibiotics) or long-term (such as the risk of skin cancer caused by ultraviolet radiation, or the effects of systemic corticosteroids on bones). The use of antibiotics and antivirals may theoretically induce resistance to bacteria and viruses, thus affecting not only the individual but also the community as a whole.</P>
<P>Many questions are unanswered in the treatment of pityriasis rosea. It is unknown whether many of the available treatments can modify the disease course, relieve the itch, or improve the quality of life. A systematic review will help determine: the most effective therapies; when and for whom they should be used; the duration of treatment; possible risks and side effects; and the level of treatment acceptability. The review will also enable an assessment of the level and quality of the evidence that is currently available, and identify areas of uncertainty or gaps in knowledge that require further research.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of interventions used in the management of pityriasis rosea. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-06 08:46:45 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-07-24 13:30:57 +0100" MODIFIED_BY="Cathy Bennett">
<CRIT_STUDIES>
<P>All randomised controlled trials that evaluate the effectiveness of interventions for pityriasis rosea.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Any individual who has been diagnosed with pityriasis rosea by a medical practitioner.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-07-24 13:30:13 +0100" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">(1) Topical therapy</HEADING>
<UL>
<LI>Emollients</LI>
<LI>Antihistamine creams or ointments</LI>
<LI>Corticosteroid creams or ointments</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Light therapy</HEADING>
<UL>
<LI>Sunlight</LI>
<LI>Artificial ultraviolet light therapy</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Systemic therapy</HEADING>
<UL>
<LI>Oral antihistamines</LI>
<LI>Oral corticosteroids</LI>
<LI>Oral antibiotics</LI>
<LI>Oral antiviral agents</LI>
</UL>
<P>The interventions can be either single therapy, or combination therapy. The comparators can be no treatment, placebo, vehicle only, another active compound, or placebo radiation treatment.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-24 13:30:57 +0100" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">Timing of outcome assessment</HEADING>
<P>We chose 2 weeks as people without any active treatment usually have spontaneous recovery in between 2 and 12 weeks. If there is any improvement after two weeks with active treatment, it is difficult to differentiate whether the improvement is due to spontaneous recovery from the disease or due to the treatment.</P>
</SUBSECTION>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-07-24 13:30:54 +0100" MODIFIED_BY="Cathy Bennett">
<P>(i) The proportion of participants with good or excellent rash improvement within two weeks, as rated by the participant.<BR/>(ii) The proportion of participants with resolution of itch within two weeks, as rated by the participant.<BR/>(iii) Reduction in itch score within two weeks, as rated by the participant.</P>
<P>'Reduction in itch score within two weeks, as rated by the participant' has been added to the primary outcome measures because we decided that it is equally as important as 'the proportion of participants with resolution of itch within two weeks, as rated by the participant'.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-07-24 13:30:57 +0100" MODIFIED_BY="Cathy Bennett">
<P>(iv) The proportion of participants with good or excellent rash improvement within two weeks, as rated by a medical practitioner.<BR/>(v) Improvement in quality of life as rated by the participant by the use of questionnaires or other methods.<BR/>(vi) Serious adverse events, i.e. serious enough to require withdrawal of the treatment.<BR/>(vii) Minor participant reported adverse events not requiring withdrawal of the treatment.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-24 13:44:49 +0100" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">Language</HEADING>
<P>No language restrictions were imposed and translations were sought where necessary.</P>
</SUBSECTION>
<ELECTRONIC_SEARCHES MODIFIED="2008-07-24 13:39:46 +0100" MODIFIED_BY="Cathy Bennett">
<P>We searched the Cochrane Skin Group Specialised Register in December 2004 using the following terms:<BR/>pityriasis and (rosea or Gibert or Vidal or circinata or marginata or maculata)</P>
<P>We searched the Cochrane Central Register of Controlled Clinical Trials (CENTRAL) from <I>The Cochrane Library</I> (Issue 4, 2004) using the search strategy in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.<BR/>
</P>
<P>We searched MEDLINE (from 1966 to January week 2, 2005) using the search strategy in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>We searched EMBASE (from 1976 to January week 2, 2005) using the search strategy in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
<P>We searched LILACS (from 1982 to January 2005) using the search strategy in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
<P>We searched BIOSIS Preview (from 1980 to January 2005), We searched this using the search strategy in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>.<BR/>
</P>
<P>We searched the metaRegister of Controlled Trials, the UK NHS Trusts Clinical Trials Register and Clinicaltrials.gov for ongoing trials on www.controlled-trials.com using the search strategy in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-07-24 13:44:49 +0100" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">References from published studies</HEADING>
<P>We looked at the bibliographies of the included and excluded studies and scanned for possible references to RCTs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Unpublished literature</HEADING>
<P>The pharmaceutical industry was contacted in an attempt to obtain unpublished trial data. Electronic addresses of leading researchers possibly involved in this field were searched for, in electronic databases, to obtain additional published and unpublished trials. We wrote to those trial authors to try to locate trials. No RCTs were obtained.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Conference proceedings</HEADING>
<P>The abstracts from major dermatology conference proceedings were scanned for further RCTs. The CAB Abstracts database was searched using the following text words in Ovid:<BR/>Pityriasis rosea, Pityriasis vidal, Pityriasis circinata, Pityriasis and marginata. There were no further attempts to locate abstracts.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>We searched PubMed for adverse effects using the strategy in <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>.</P>
<P>The articles usually described reports of medications that can produce "Pityriasis rosea like" reactions and were not related with medicament toxicity when treating PR.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-06 08:46:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Not all headings activated here.&lt;/p&gt;&lt;p&gt;text reorganised a bit to fit available headings.&lt;/p&gt;&lt;p&gt;Author please check risk of bias heading as this term not directly interchangeable with methodological quality.&lt;/p&gt;" NOTES_MODIFIED="2008-08-06 08:46:45 +0100" NOTES_MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">General</HEADING>
<P>Where there was uncertainty, trial authors were contacted for clarification. A consumer (FC) was involved throughout the review process to ensure the readability of the final review.</P>
<P>
<B>Other aspects of quality<BR/>
</B>The methods of diagnosis were slightly different for the three trials. Although it was not explicitly stated in all three studies whether the diagnoses of pityriasis rosea were made by dermatologists, all three studies were conducted in dermatology departments. We thus believe that all three studies incur a high degree of certainty that the participants had PR. All three trials did not specifically exclude drug-induced PR.<BR/>
<B>
<BR/>
</B>All three trials documented baseline assessment of the participants for age, sex, and duration of pityriasis rosea. All three trials had some documentation of the distribution and extent of eruption. The trial by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK> documented the presence or absence of itch at baseline. The trial by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK> documented the severity of itch with a visual analogue scale. The trial by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK> did not document the presence or severity of itch at baseline.<BR/>
<B>
<BR/>
</B>The objectives and outcome measures were clearly defined for the studies by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK> and <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>. In the study by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>, the disappearance of symptoms and rash were assessed together. Symptoms were not specified as itch. The authors had to assume that the symptoms were limited to itch only.</P>
<P>The drug doses and duration of treatment were clearly defined in the studies by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK> and <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>. In the study by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>, the drug doses were clearly defined. How the duration of treatment was decided was unclear. All three trials did not comprehensively document the use of previous medications after the appearance of rash, but before consultation.</P>
<P>Overall, we believe that the methodological quality is poor for the study by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>, fair for the study by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>, and good for the study by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>.</P>
</SUBSECTION>
<STUDY_SELECTION MODIFIED="2008-07-24 13:45:25 +0100" MODIFIED_BY="Cathy Bennett">
<P>Two authors (BD, LR) checked the titles and abstracts identified from the searches. If it was clear that the study did not refer to a randomised controlled trial on PR, it was excluded. Quasi-randomised trials, where allocation was by non-random methods such as alternation, or was based on characteristics such as date of birth, name or case number, were excluded. Two authors (BD, LR) independently assessed each study to determine whether it met the pre-defined selection criteria, any differences being resolved through discussion with the review team. There was no blinding of the reviewer as to the origin, or conclusions of the article for eligibility assessment, data extraction or quality assessment. Excluded studies were listed in the Characteristics of Excluded Studies Table and reasons for exclusion given.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-24 13:47:20 +0100" MODIFIED_BY="Cathy Bennett">
<P>Two authors (GC and BD) independently performed data extraction and a third team member (VS) resolved the differences. Any missing data was obtained from the trial authors where possible. A data collection form was developed and piloted in order to summarise the trials. One author (LR) checked and entered the data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-24 14:10:34 +0100" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">Assessment of methodological quality</HEADING>
<P>The quality assessment included an evaluation of the following components for each included study, since there is some evidence that these are associated with biased estimates of treatment effect (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>):<BR/>(a) the method of generation of the randomisation sequence;<BR/>(b) the method of allocation concealment - it was considered adequate if the assignment cannot be foreseen;<BR/>(c) who was blinded / not blinded (participants, clinicians, outcome assessors);<BR/>(d) how many participants were lost to follow up in each arm and whether participants were analysed in the groups to which they were originally randomised (intention-to-treat).</P>
<P>In addition the quality assessment also included:<BR/>(e) degree of certainty that the participants have PR; e.g. whether the diagnoses were made by primary care physicians or dermatologists;<BR/>(f) whether participants with drug-induced PR-like rashes were excluded;<BR/>(g) baseline assessment of the participants for age, sex, duration and severity of PR;<BR/>(h) aims, interventions (including drug doses and duration of treatment) and outcome measures clearly defined.</P>
<P>We recorded the information in a Table of Quality Criteria (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) and a description of the quality of each study was given based on a summary of the above components. We used the results of the methodological quality assessment as the basis for sensitivity analysis and not as exclusion criteria.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-07-24 13:47:27 +0100" MODIFIED_BY="Cathy Bennett">
<P>For studies with a similar type of intervention and comparator, e.g. oral erythromycin versus placebo, we performed a meta-analysis to calculate a weighted treatment effect across trials using a random effects model. Where it was not possible to perform a meta-analysis, we summarised the data for each trial. Data are presented as risk ratios (RR) with 95% confidence intervals, and as numbers need to treat (NNT) for dichotomous outcomes.</P>
<P>The participant rated global assessments of rash and itch improvement were the primary outcome measures if available. If they were not available, the medical practitioner global rating was used. Both measures were taken into account where both were available. No attempt was made to combine these measures as they are often not well-correlated. There exists evidence that, before treatment, rash severity in PR as rated by the medical practitioner is not correlated with effects on quality of life as rated by the participant (<LINK REF="REF-Chuh-2005a" TYPE="REFERENCE">Chuh 2005a</LINK>).</P>
<P>Non-randomised controlled studies were listed but not discussed further.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-06 09:35:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-08-06 09:16:11 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2008-07-24 13:48:40 +0100" MODIFIED_BY="Cathy Bennett">
<P>We found 16 studies. The studies investigated various topical treatments (<LINK REF="STD-Yamashita-1988" TYPE="STUDY">Yamashita 1988</LINK>), ultraviolet therapy (<LINK REF="STD-Merchant-1974" TYPE="STUDY">Merchant 1974</LINK>; <LINK REF="STD-Arndt-1983" TYPE="STUDY">Arndt 1983</LINK>; <LINK REF="STD-Chen-1994" TYPE="STUDY">Chen 1994</LINK>; <LINK REF="STD-Leenutaphong-1995" TYPE="STUDY">Leenutaphong 1995</LINK>; <LINK REF="STD-Valkova-2004" TYPE="STUDY">Valkova 2004</LINK>), and systemic treatments (<LINK REF="STD-Roxas" TYPE="STUDY">Roxas</LINK>; <LINK REF="STD-Gutowski-1950" TYPE="STUDY">Gutowski 1950</LINK>; <LINK REF="STD-Kalbarczyk-1957" TYPE="STUDY">Kalbarczyk 1957</LINK>; <LINK REF="STD-Salin-1957" TYPE="STUDY">Salin 1957</LINK>; <LINK REF="STD-Grobe-1984" TYPE="STUDY">Grobe 1984</LINK>; <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>; <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>; <LINK REF="STD-Sharma-2000" TYPE="STUDY">Sharma 2000</LINK>; <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>; <LINK REF="STD-Karpouzis-2003" TYPE="STUDY">Karpouzis 2003</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-08-06 09:16:11 +0100" MODIFIED_BY="[Empty name]">
<P>Three randomised trials (<LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>; <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>; <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>) met the inclusion criteria. One study (<LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>) was published but not identified in any of the electronic databases, conference proceedings, or references. One author (BD) identified this article by hand-searching. One study (<LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>) was unpublished. The same author (BD) identified this article by direct correspondence with the trialists. The data from one study (<LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>) was extracted from an abstract in Chinese. We translated the abstract into English. We failed to obtain full text of the study from the trialists, despite repeated attempts. Futher details of each included study are given in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
<P>All three trials were performed in dermatology departments, in hospital settings. The age and sex distributions were similar in the three studies. As the three included studies investigated different interventions and different outcome measures, pooling of data for analysis was not feasible.</P>
<P>In a parallel-group study by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>, 85 participants with pityriasis rosea were recruited. The mean age of participants was 22.1 years: 38 were men and 47 were women. The interventions investigated were the oral antihistamine dexchlorpheniramine and the oral corticosteroid betamethasone. The participants were randomised to receive one of three combinations of the interventions: (1) oral dexchlorpheniramine tablet 4 mg twice daily for two weeks, then once daily for another two weeks (27 participants); (2) oral betamethasone tablet (500 mcg) twice daily for two weeks, then daily for another two weeks (31 participants), and (3) oral betamethasone (250 mcg) - dexchlorpheniramine (2 mg) combination tablet twice daily for two weeks, then once daily for another two weeks (27 participants). The participants were followed up for 12 weeks. Assessment was done on day 3, then weekly for 4 weeks, then every 4 weeks until week 12. The major outcome measures were the proportion of participants with resolution of itch, as rated by the participants (a primary outcome measure), and the proportion of participants with good or excellent rash improvement as rated by the medical practitioner (reported as increase or decrease in the number of lesions) (a secondary outcome measure). Other outcome measures included adverse effects of the treatment. Ultimately, 25 (93%), 29 (94%), and 17 (63%) participants in the 3 groups completed the trial.</P>
<P>In the trial by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>, 40 participants with pityriasis rosea were recruited to investigate the effectiveness of the oral antibiotic erythromycin. There were 18 men and 22 women and the mean age of the participants was 25.9 years. The participants were randomised to receive either one oral erythromycin capsule 250 mg (as erythromycin stearate) every six hours for two weeks (20 participants), or one oral placebo (flour) capsule of the same appearance, weight, and packaging every six hours for two weeks (20 participants). The participants were assessed weekly for six weeks. The major outcome measures were the mean decrease in itch as assessed by the participants using visual analogue scale (a primary outcome measure), and the proportion of participants with good or excellent rash improvement as rated by a medical practitioner (a secondary outcome measure). Other outcome measures were adverse effects of the treatment. Ultimately, 17 (85%) participants in the treatment group and 17 (85%) participants in the placebo group completed the trial.</P>
<P>In the trial by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>, 23 participants with PR with mean age of 27.2 years were recruited. There were 15 men and 8 women. The study investigated glycyrrhizin, which is the active ingredient of liquorice root, and has been used for many medical conditions including peptic ulcer and cough. The anaesthetic procaine was used in the study as a placebo. The participants were randomised into two groups. The first group (12 participants) was given (80 ml) glycyrrhizin and (500 ml)10% glucose solution intravenously for 5 to 11 days. The second group (11 participants) were given 300 to 600 mg procaine and (500 ml) 10% glucose solution for 10 to 20 days. The participants were followed for 10 to 20 days. The interval of follow-up was not explicitly stated. The main outcome measure was the proportion of participants with good or excellent rash improvement as rated by the medical practitioner (reported as disappearance of symptoms and rash), a secondary outcome measure. All participants in both groups completed the trial.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-07-24 13:50:30 +0100" MODIFIED_BY="Cathy Bennett">
<P>We excluded 13 out of the 16 studies because there was no randomisation. Four studies on artificial ultraviolet therapy (<LINK REF="STD-Merchant-1974" TYPE="STUDY">Merchant 1974</LINK>; <LINK REF="STD-Arndt-1983" TYPE="STUDY">Arndt 1983</LINK>; <LINK REF="STD-Leenutaphong-1995" TYPE="STUDY">Leenutaphong 1995</LINK>; <LINK REF="STD-Valkova-2004" TYPE="STUDY">Valkova 2004</LINK>) were bilateral comparison studies. In two studies (<LINK REF="STD-Arndt-1983" TYPE="STUDY">Arndt 1983</LINK>; <LINK REF="STD-Leenutaphong-1995" TYPE="STUDY">Leenutaphong 1995</LINK>), the right sides of all participants were treated with ultraviolet-B, while the left sides of all participants were shielded (<LINK REF="STD-Arndt-1983" TYPE="STUDY">Arndt 1983</LINK>) or given placebo ultraviolet-A treatment (<LINK REF="STD-Leenutaphong-1995" TYPE="STUDY">Leenutaphong 1995</LINK>). In the study by <LINK REF="STD-Valkova-2004" TYPE="STUDY">Valkova 2004</LINK>, two groups of participants were recruited. The first group of participants received ultraviolet-B to their right sides and placebo ultraviolet-A to their left sides. The second group received ultraviolet-B to their whole bodies. In the study by <LINK REF="STD-Merchant-1974" TYPE="STUDY">Merchant 1974</LINK>, one side of all participants was treated with ultraviolet light while the other side was untreated. In two studies comparing oral erythromycin and placebo (<LINK REF="STD-Roxas" TYPE="STUDY">Roxas</LINK>, <LINK REF="STD-Sharma-2000" TYPE="STUDY">Sharma 2000</LINK>), participants were alternately assigned to treatment and control groups. See Table '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' for full list of excluded studies.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-08-06 09:20:51 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Data in Quality components table could be moved to Risk of bias tables for each study Author/RGC to decide.  Added text to this section so that I could link to the table.&lt;/p&gt;" NOTES_MODIFIED="2008-08-06 09:20:51 +0100" NOTES_MODIFIED_BY="[Empty name]">
<P>A table of quality components for each study is provided in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>
</P>
<ALLOCATION MODIFIED="2008-07-24 13:52:59 +0100" MODIFIED_BY="Cathy Bennett">
<P>The trial by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK> used a randomised table provided by a statistician for the generation of the randomisation sequence. We consider this adequate. The methods of allocation concealment were, however, unclear. The trial by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK> used a computer-generated table of random numbers. The trialists adopted a third party approach in allocation concealment. Four separate trialists conducted the following four tasks: (1) assessing the participants for inclusion or exclusion, (2) randomising the participants into Treatment A and Treatment B, (3) assigning oral erythromycin and placebo to either Treatment A and Treatment B, and (4) dispensing test medications to participants. Selection bias was thus minimised in this study, and we consider such adequate. No information was given in the <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK> study on the method of generation of the randomisation sequence. Whether allocation was concealed or not was not reported. We consider such unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2008-07-24 13:53:01 +0100" MODIFIED_BY="Cathy Bennett">
<P>In the study by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>, the outcome assessors, participants and clinicians were blinded after allocation and when assessing outcomes. The method of blinding was not stated. Whether the analyses were performed by a person having no knowledge of the allocation was not stated. We consider such unclear. In the study by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>, after randomisation and allocation, the outcome assessors, participants and clinicians were blinded when assessing rash resolution and when assessing itch improvement. A trialist who was not involved in randomisation and allocation concealment conducted the clinical evaluation. An independent statistician being blinded regarding the identities of treatment groups performed data analyses. Performance bias and detection bias were thus minimised in this study, and we consider such adequate. Whether trialists and participants were blinded after allocation and when assessing outcomes was not stated in the trial by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>. We consider such unclear.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2008-08-06 09:20:51 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Follow-up and exclusions</HEADING>
<P>Two (7%), two (6%), and ten (37%) participants were lost to follow up in the three arms in the study by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>. No reason was given by the trialists for the large number of participants who dropped out in the third arm. Intention-to-treat analyses were not performed: participants who did not complete four weeks of treatment were not included in the analysis. Three (15%) participants were lost in each arm of the study by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK> because they did not follow up after the first week of treatment. The evaluable participants were analysed in the groups to which they were originally randomised. There was no loss to follow up in the trial by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>.</P>
</SUBSECTION>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2008-08-05 16:02:47 +0100" MODIFIED_BY="[Empty name]">
<P>There was no selective reporting of outcomes, time points, subgroups or analyses in all three trials.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2008-07-24 13:53:22 +0100" MODIFIED_BY="Cathy Bennett" NOTES="&lt;p&gt;'Quality' or 'risk of bias' - author to check&lt;/p&gt;" NOTES_MODIFIED="2008-07-24 13:53:22 +0100" NOTES_MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="4">Other aspects of quality</HEADING>
<P>The methods of diagnosis were slightly different for the three trials. Although it was not explicitly stated in all three studies whether the diagnoses of pityriasis rosea were made by dermatologists, all three studies were conducted in dermatology departments. We thus believe that all three studies incur a high degree of certainty that the participants had PR. All three trials did not specifically exclude drug-induced PR.<BR/>
<B>
<BR/>
</B>All three trials documented baseline assessment of the participants for age, sex, and duration of pityriasis rosea. All three trials had some documentation of the distribution and extent of eruption. The trial by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK> documented the presence or absence of itch at baseline. The trial by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK> documented the severity of itch with a visual analogue scale. The trial by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK> did not document the presence or severity of itch at baseline.<BR/>
<B>
<BR/>
</B>The objectives and outcome measures were clearly defined for the studies by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK> and <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>. In the study by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>, the disappearance of symptoms and rash were assessed together. Symptoms were not specified as itch. The authors had to assume that the symptoms were limited to itch only.</P>
<P>The drug doses and duration of treatment were clearly defined in the studies by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK> and <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>. In the study by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>, the drug doses were clearly defined. How the duration of treatment was decided was unclear. All three trials did not comprehensively document the use of previous medications after the appearance of rash, but before consultation.</P>
<P>Overall, we believe that the methodological quality is poor for the study by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>, fair for the study by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>, and good for the study by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-06 09:35:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;I have taken comparison number out of the headings and linked to the analyses in the text - author please check.&lt;/p&gt;" NOTES_MODIFIED="2008-08-06 09:35:37 +0100" NOTES_MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(i) The proportion of participants with good or excellent rash improvement within two weeks, as rated by the participant</HEADING>
<P>None of the studies measured this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(ii) The proportion of participants with resolution of itch within two weeks, as rated by the participant (1 study)</HEADING>
<P>One trial (<LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>) measured this outcome. The proportion of participants with resolution of itch, as rated by the participants, was compared between (1) oral dexchlorpheniramine (4 mg) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), (2) oral betamethasone (500 mcg) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>), and (3) combination of oral betamethasone (250 mcg) and oral dexchlorpheniramine (2 mg) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). There was no statistically significant difference between the three groups of participants after two weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(iii) Reduction in itch score within two weeks, as rated by the participant (1 study; comparison 02.03)</HEADING>
<P>The trial by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK> measured the mean reduction in itch score (using a visual analogue scale) after two weeks of treatment. Erythromycin significantly reduced the itch scores (P value less than 0.0027) showing a difference of 3.95 points (95% CI 3.37 to 4.53) compared with placebo. This result was from 17 participants on erythromycin and 17 participants on placebo; no information was available on 3 participants in each group.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(iv) The proportion of participants with good or excellent rash improvement within two weeks, as rated by the medical practitioner (3 studies)</HEADING>
<P>All three trials measured this outcome. For the trial by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>, there was no significant difference in the proportion of participants with good or excellent rash improvement, as rated by the medical practitioner, between oral dexchlorpheniramine (4 mg ) and oral betamethasone (500 mcg) at two weeks (RR 0.66, 95% CI 0.42 to 1.06; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). 500 mcg of oral betamethasone was significantly better than the combination of oral betamethasone (250 mcg) and dexchlorpheniramine (2 mg) in clearing the rash at two weeks (21/29; 1/17; RR 12.31, 95% CI 1.81 to 83.52; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). Oral dexchlorpheniramine (4 mg) was significantly better than the combination of oral betamethasone (250 mcg) and oral dexchlorpheniramine (2 mg) in clearing the rash at two weeks (12/25 vs 1/17; RR 8.16, 95% CI 1.17 to 57.05; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
<P>The study by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK> reported that 13 out of 17 (76.5%) participants on oral erythromycin who completed the study, and 1 out of 17 (5.9%) participants on oral placebo who completed the study, achieved excellent rash improvement (reported as complete cure) in two weeks (RR 13.00; 95% CI 1.91 to 88.64; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). The NNT was 1.42 meaning that for approximately every two participants treated with 250 mg of erythromycin every six hours for two weeks, one participant would achieve complete clearing of the rash within two weeks.</P>
<P>The trial by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK> reported that 10 days after commencement of treatment, 12 out of 12 (100.0%) participants on intravenous glycyrrhizin and glucose, and 8 out of 11 participants (72.7%) on intravenous procaine and glucose, achieved good or excellent rash improvement (reported as disappearance of symptoms and rash, or disappearance or obvious relief of symptoms, or disappearance of rash by more than 70%). The trialists defined the disappearance of symptoms and rash as "cure". Taking this outcome measure alone, they reported that 11 out of 12 (91.7%) participants on intravenous glycyrrhizin and glucose and 3 out of 11 (27.3%) participants on intravenous procaine and glucose achieved "cure" (RR 1.38, 95% CI 0.96 to 1.97; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The size of the trial is too small for definite conclusions to be drawn.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(v) Improvement in quality of life within two weeks, as rated by the participant by questionnaires or other methods</HEADING>
<P>None of the trials measured this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(vi) Serious adverse events, i.e. serious enough to require withdrawal of the treatment (2 studies)</HEADING>
<P>Two of the trials (<LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>; <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>) measured this outcome. Neither reported any serious adverse event.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(vii) Minor participant reported adverse events not requiring withdrawal of the treatment (2 studies)</HEADING>
<P>Two of the trials measured this outcome. The trial by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK> reported no minor adverse event in any of the three intervention groups. The trial by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK> reported three participants with gastrointestinal upset and nausea. Two participants were in the oral erythromycin group and one was in the oral placebo group (RR 2.00, 95% CI 0.20 to 20.04; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). The effects were mild and tolerable for all three participants, with no drop-out and no need for treatment with an antacid. These side effects are common for erythromycin.</P>
<P>The study by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK> did not quantitatively measure adverse events. The trialists reported qualitatively that adverse effects were less frequent and less severe for glycyrrhizin than for procaine.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION NOTES="&lt;p&gt;No subheadings activated here, did not seem appropriate - author to check&lt;/p&gt;">
<P>Pityriasis rosea was first accurately described by the French dermatologist Camille Melchior Gibert in 1860. Many trials have been conducted to identify its cause, however, the number of controlled trials on its treatment is small.</P>
<P>Diagnostic criteria are a concern in RCTs and other forms of research on pityriasis rosea. Only three trials met the inclusion criteria for this review and each used different diagnostic criteria. While one trial (<LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>) included participants with atypical features, another study (<LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>) explicitly excluded participants with atypical features. The third study (<LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK>) did not mention whether people with atypical rash were included. This discrepancy does not allow results of the trials to be directly compared with one another.</P>
<P>The trial by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK> adopted clearly stated diagnostic criteria, but they have not been validated. Many participants with so-called typical pityriasis rosea can have some atypical features. The distinction between typical and atypical PR is never a straightforward task (<LINK REF="REF-Chuh-2005b" TYPE="REFERENCE">Chuh 2005b</LINK>). The use of validated diagnostic criteria might standardise the inclusion of participants in future clinical trials and allow the results to be compared. The results can then be more validly applied in clinical practice.</P>
<P>Lesional biopsy for histopathology was performed for all participants in the study by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>. Lesional histopathological changes in pityriasis rosea are non-specific, and can be used to substantiate the diagnosis and exclude important differential diagnoses. For participants with a typical PR eruption, we do not think that it is necessary to carry out invasive lesional biopsy. Insisting on lesional biopsy for all participants might also lead to a lower recruitment rate in RCTs and other types of research for PR, thus causing a potential threat to external validity.</P>
<P>Pityriasis rosea is a self-limiting condition. Spontaneous resolution is very likely between 2 and 12 weeks. As there exists no universally accepted method of active intervention, we believe that the standard comparator should be placebo. The <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK> study did not use a placebo and compared three active interventions. Although some of the comparisons were statistically more effective than others at certain time points, it is impossible to determine the clinical importance of these as there was no comparison with natural progress. Any improvements beyond 2 weeks cannot be directly attributed to treatment as spontaneous remission is likely at 2 to 12 weeks. We therefore did not evaluate for outcome measures beyond two weeks.</P>
<P>In pityriasis rosea there is no correlation between the extensiveness of the rash, the severity of itch, and effects on the quality of life (<LINK REF="REF-Chuh-2005a" TYPE="REFERENCE">Chuh 2005a</LINK>). Some people with extensive rash might not be experiencing any itch at all. As PR rarely involves the face, treatment given with the aim of hastening the resolution of rash might not have any material benefit . None of the studies investigated the impact of treatment on the quality of life. The study by <LINK REF="STD-Zhu-1992" TYPE="STUDY">Zhu 1992</LINK> even lumped symptoms (itch) and signs (rash) together and evaluated them as a single outcome measurement.</P>
<P>The mechanisms of action for oral erythromycin, oral betamethasone, and oral dexchlorpheniramine are unknown. Apart from its effects as an antibiotic, erythromycin (one of a group of antibiotics known as macrolides) also exerts anti-inflammatory and modulating effects on the immune system (<LINK REF="REF-Labro-1998" TYPE="REFERENCE">Labro 1998</LINK>). Its efficacy therefore does not necessarily support bacterial infection(s) or exclude viral infection(s) from being the cause of pityriasis rosea. The corticosteroid, oral betamethasone also exerts anti-inflammatory actions. Its effect in PR might be related to inflammation and autoimmunity being possible components in the immunological pathology of pityriasis rosea (<LINK REF="REF-Chuh-2003d" TYPE="REFERENCE">Chuh 2003d</LINK>). Oral dexchlorpheniramine is a sedative histamine-1 antagonist, and as such it exerts non-specific anti-itching effects. The mechanism for its efficacy, if any, on rash resolution in pityriasis rosea is unknown. It is known that viral rashes may be associated with atopy and hyper-immunoglobulinaemia E states (<LINK REF="REF-Ricci-2003" TYPE="REFERENCE">Ricci 2003</LINK>). Whether this is related to the action of oral dexchlorpheniramine in pityriasis rosea is unknown.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Present treatments for PR are largely empirical and many different types of treatment are used. There is inadequate evidence for the efficacy of topical emollients, topical antihistamines, topical corticosteroids, sunlight, artificial ultraviolet therapy, systemic antihistamines, systemic corticosteroids, systemic antiviral agents, and intravenous glycyrrhizin in PR. Although oral betamethasone (4 mg) and oral dexchlorpheniramine (500 mcg) were both found to be significantly better for rash clearance than the combination of oral betamethasone (250 mcg) and oral dexchlorpheniramine (2 mg) in the early weeks of the trial by <LINK REF="STD-Lazaro_x002d_Medina-1996" TYPE="STUDY">Lazaro-Medina 1996</LINK>, all three interventions were not compared with placebo. Spontaneous remission cannot be excluded. There were also inadequacies of study design. Further investigations need to be performed to ascertain the benefit of these interventions in PR.</P>
<P>There is some evidence that oral erythromycin at a dose of 250 mg every 6 hours for 2 weeks is effective in hastening the rash resolution and reducing the itch in PR. However it should be noted that these results are from a single study by Villarma with a relatively small number of individuals included. Publication bias and internal bias are still possible. The potential benefit from oral erythromycin must be weighed against the potential for adverse effects. In the study by <LINK REF="STD-Villarama" TYPE="STUDY">Villarama</LINK>, only 2 (12%) out of 17 people with PR treated with erythromycin reported gastrointestinal reactions. This contrasts significantly with incidences of gastrointestinal side effects of 25.0% (<LINK REF="REF-Sato-1975" TYPE="REFERENCE">Sato 1975</LINK>) and 51.4% (<LINK REF="REF-Carter-1987" TYPE="REFERENCE">Carter 1987</LINK>) in studies using oral erythromycin to treat other diseases. Our experience with oral erythromycin also suggests that more than 12% develop gastrointestinal side effects.</P>
<P>PR is a self-limiting condition and spontaneous recovery is expected in 2 to 12 weeks without active treatment. It is unusual for the face to be affected and many people with PR do not itch at all. The severity of itch and effects on quality of life are not correlated with the extent of the rash. When choosing treatment options the severity of itch, the extent and distribution of the rash, and potential adverse effects of the treatment all need to be taken into consideration.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The absence of evidence of efficacy for many treatments in pityriasis rosea does not necessarily imply that they are not effective. We recommend more research to investigate efficacy of these treatments, particularly oral erythromycin or other macrolide antibiotics. Macrolides should especially be investigated as they have anti-inflammatory and immuno-modulating effects in addition to their antibiotic (antibacterial) actions (<LINK REF="REF-Labro-1998" TYPE="REFERENCE">Labro 1998</LINK>). We also recommend randomised controlled trials to investigate the treatments for PR that are commonly used by dermatologists. For example, topical corticosteroids versus placebo, or emollients versus placebo for people with pityriasis rosea who are symptomatic. The results of these studies may also shed light on the cause of PR.</P>
<P>We advocate that further research should be conducted to validate a set of diagnostic criteria for PR. Future clinical trials on PR might then adopt such validated diagnostic criteria so that the results can be directly and validly compared with one another. We believe that consent for lesional biopsy for histopathology should not be mandatory as an inclusion criteria for enrolment in trials.</P>
<P>As there is no universally accepted active intervention for PR, we suggest that future clinical trials for PR should include placebo as a control, rather than merely comparing several potentially active interventions against one another. The time frame for assessing outcomes should preferably be within two weeks, as spontaneous remission cannot be excluded after two weeks. If the time frame for assessing outcomes is beyond two weeks, the study should be powerful enough to compare treatment versus placebo in order to demonstrate meaningful reductions in average time course to resolution of rash or symptoms.</P>
<P>We advocate that apart from baseline assessment of extensiveness of the rash. The baseline assessment of symptoms (mainly itch) and effects on quality of life should be well documented in any future clinical trials on pityriasis rosea. We also advocate that validated quality of life indexes should be adopted as measures of outcome. Researchers should be alerted to the fact that many people with PR have little or no itch in the first place. A diagnostic label in Latin may be given but the condition may not bother the person at all. The potential adverse effects of any intervention should be balanced against potential benefit, if any, for this group of affected people.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Professor Hywel Williams and Dr Tina Leonard of the Cochrane Skin Group for their supervision and assistance in this review. We thank Dr Finola Delamere, Trials Search Co-ordinator of the Cochrane Skin Group, for her assistance with searching the trials. We thank Dr Gosia Bala of the Tobacco Addiction Group for searching for manuscripts in Polish for us, and for contacting original trialists for further data. We thank Dr Katja Schmidt, skin group author, for searching for manuscripts in German for us. We thank Dr Tetsuri Matsumura, Skin Group author, for searching for manuscripts in Japanese for us. We thank Dr Leigh Martin, Skin Group author, for searching for manuscripts in Italian for us. We thank Dr Taixiang Wu, Skin Group author, for retrieving manuscripts in Mainland China for us. We thank Ms Jannie Hedegaard, Nordic Cochrane Centre, for retrieving articles for us. We also acknowledge Dr Nilesh Morar for her involvement in the early phase of drafting the protocol.</P>
<P>Figures 01 and 02 were previously published by us in the <I>Journal of the European Academy of Dermatology and Venereology</I> (<LINK REF="REF-Chuh-2003b" TYPE="REFERENCE">Chuh 2003b</LINK>; <LINK REF="REF-Chuh-2005b" TYPE="REFERENCE">Chuh 2005b</LINK>), and are reproduced in this review with the kind permission of Ms Zoe Ellams, Permissions Co-ordinator, Blackwell Publishing.</P>
<P>The Cochrane Skin Group would like to thank the following people who were external referees for this review: Stuart Cohen and Cameron Kennedy (external content experts), Jack Tweed and Rosemary Humphreys (consumers).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Draft the protocol (AC, BD, LR, FC)<BR/>Search for trials (LR, VS)<BR/>Obtain copies of trials (GC, VS)<BR/>Select which trials to include (BD, LR; AC as arbiter)<BR/>Extract data from trials (BD, GC, VS)<BR/>Enter data into RevMan (LR)<BR/>Carry out the analysis (GC, AC)<BR/>Interpret the analysis (GC, AC)<BR/>Draft the final review (AC, LR, SG, FC)<BR/>Update the review (AC)</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-06 10:06:46 +0100" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Lazaro_x002d_Medina-1996" NAME="Lazaro-Medina 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lazaro-Medina A, Villena-Amurao C, Dy-Chua NS, Sit-Toledo MSW, Villanueva B</AU>
<TI>A clinicohistopathologic study of a randomized double-blind clinical trial using oral dexchlorpheniramine 4 mg, betamethasone 500 mcg and betamethasone 250 mcg with dexchlorpheniramine 2 mg in the treatment of pityriasis rosea: a preliminary report</TI>
<SO>Journal of the Philippine Dermatological Society</SO>
<YR>1996</YR>
<VL>5</VL>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Villarama" NAME="Villarama" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Villarama C, Lansang P</AU>
<TI>The efficacy of erythromycin stearate in pityriasis rosea: a randomized, double-blind, placebo-controlled trial</TI>
<SO>(unpublished)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-1992" NAME="Zhu 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhu QY</AU>
<TI>The observation of curative effects of glycyrrhizin in treating pityriasis rosea</TI>
<SO>Journal of Clinical Dermatology</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>1</NO>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Arndt-1983" NAME="Arndt 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arndt KA, Paul BS, Stern RS, Parrish JA</AU>
<TI>Treatment of pityriasis rosea with UV radiation</TI>
<SO>Archives of Dermatology</SO>
<YR>1983</YR>
<VL>119</VL>
<NO>5</NO>
<PG>381-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1994" NAME="Chen 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chen ZY</AU>
<TI>UV-N j type phototherapy instrument for pityriasis rosea</TI>
<SO>Chinese Journal of Dermatovenereology</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>2</NO>
<PG>121</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grobe-1984" NAME="Grobe 1984" YEAR="1984">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Grobe JW</AU>
<TI>Virostatic effect in the treatment of pityriasis rosea irritata with moroxydine-HCI</TI>
<SO>Derm Beruf Umwelt</SO>
<YR>1984</YR>
<VL>32</VL>
<NO>1</NO>
<PG>25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gutowski-1950" NAME="Gutowski 1950" YEAR="1950">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gutowski W</AU>
<TI>Trial treatment of Gibert's pityriasis rosea with bismuth and penicillin</TI>
<SO>Polski tygodnik lekarski (Warsaw)</SO>
<YR>1950</YR>
<VL>5</VL>
<NO>51-52</NO>
<PG>1774-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalbarczyk-1957" NAME="Kalbarczyk 1957" YEAR="1957">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kalbarczyk K, Gutowski W</AU>
<TI>Prednisone in the treatment of Gibert's pityriasis</TI>
<SO>Wiad Lek</SO>
<YR>1972</YR>
<VL>25</VL>
<NO>7</NO>
<PG>627-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karpouzis-2003" NAME="Karpouzis 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Karpouzis, A. et al</AU>
<TI>Clarithromycin in pityriasis rosea: a clinical study</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>Suppl 3</NO>
<PG>157</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leenutaphong-1995" NAME="Leenutaphong 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Leenutaphong V, Jiamton S</AU>
<TI>UVB phototherapy for pityriasis rosea: a bilateral comparison study</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1995</YR>
<VL>33</VL>
<NO>6</NO>
<PG>996-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merchant-1974" NAME="Merchant 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Merchant M, Hammond R</AU>
<TI>Controlled study of ultraviolet light for pityriasis rosea</TI>
<SO>Cutis</SO>
<YR>1974</YR>
<VL>14</VL>
<NO>4</NO>
<PG>548-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Roxas" NAME="Roxas" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Roxas MZL, Reyes RPS</AU>
<TI>Erythromycin in pityriasis rosea: a placebo-controlled clinical trial in East Avenue Medical Center</TI>
<SO>From the authors</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salin-1957" NAME="Salin 1957" YEAR="1957">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Salin RW, Curtis AC, Wheeler A</AU>
<TI>The treatment of pityriasis rosea with convalescent plasma, gamma globulin, and pooled plasma</TI>
<SO>American Medical Association Archives in Dermatology</SO>
<YR>1957</YR>
<VL>76</VL>
<NO>5</NO>
<PG>659-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharma-2000" NAME="Sharma 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sharma PK, Yadav TP, Gautam RK, Taneja N, Satyanarayana L</AU>
<TI>Erythromycin in pityriasis rosea: A double-blind, placebo-controlled clinical trial</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>2 Pt 1</NO>
<PG>241-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valkova-2004" NAME="Valkova 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Valkova S, Trashlieva M, Christova P</AU>
<TI>UVB phototherapy for pityriasis rosea</TI>
<SO>Journal of the European Academy of Dermatology &amp; Venereology</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>1</NO>
<PG>111-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamashita-1988" NAME="Yamashita 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yamashita Y</AU>
<TI>A well controlled comparative clinical study of the effect of difluprednate DFBA myser ointment on pityriasis rosea Gibert</TI>
<SO>Hifu</SO>
<YR>1988</YR>
<VL>30</VL>
<NO>5</NO>
<PG>669-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-06 10:06:46 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-06 10:06:46 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ahmed-1986" NAME="Ahmed 1986" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed MA</AU>
<TI>Pityriasis rosea in the Sudan</TI>
<SO>International Journal of Dermatology</SO>
<YR>1986</YR>
<VL>25</VL>
<PG>184-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bjornberg-1962" NAME="Bjornberg 1962" TYPE="JOURNAL_ARTICLE">
<AU>Bjornberg A, Hellgren L</AU>
<TI>Pityriasis rosea. A statistical, clinical and laboratory investigation of 826 patients and matched healthy controls</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>1962</YR>
<VL>42</VL>
<PG>50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Broccolo-2005" NAME="Broccolo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Broccolo F, Drago F, Careddu AM, Foglieni C, Turbino L, Cocuzza CE, et al</AU>
<TI>Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7</TI>
<SO>Journal of Investigative dermatology</SO>
<YR>2005</YR>
<VL>124</VL>
<PG>1234-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carter-1987" NAME="Carter 1987" TYPE="JOURNAL_ARTICLE">
<AU>Carter BL, Woodhead JC, Cole KJ, Milavetz G</AU>
<TI>Gastrointestinal side effects with erythromycin preparations</TI>
<SO>Drug Intelligence and Clinical Pharmacy</SO>
<YR>1978</YR>
<VL>21</VL>
<PG>734-738</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castanedo-2003" NAME="Castanedo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Castanedo-Cazares JP, Lepe V, Moncada B</AU>
<TI>Should we still use phototherapy for pityriasis rosea?</TI>
<SO>Photodermatology, Photoimmunology and Photomedicine</SO>
<YR>2003</YR>
<VL>19</VL>
<PG>160-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheong-1989" NAME="Cheong 1989" TYPE="JOURNAL_ARTICLE">
<AU>Cheong WK, Wong KS</AU>
<TI>An epidemiological study of pityriasis rosea in Middle Road Hospital</TI>
<SO>Singapore Medical Journal</SO>
<YR>1989</YR>
<VL>30</VL>
<PG>60-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuang-1982" NAME="Chuang 1982" TYPE="JOURNAL_ARTICLE">
<AU>Chuang TY, Ilstrup DM, Perry HO, Kurland LT</AU>
<TI>Pityriasis rosea in Rochester, Minnesota, 1969 to 1978</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1982</YR>
<VL>7</VL>
<PG>80-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuh-2001" NAME="Chuh 2001" TYPE="JOURNAL_ARTICLE">
<AU>Chuh AAT, Chiu SSS, Peiris JSM</AU>
<TI>Human herpesvirus 6 and 7 DNA in peripheral blood leukocytes and plasma in patients with pityriasis rosea by polymerase chain reaction - a prospective case control study</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>2001</YR>
<VL>81</VL>
<PG>289-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuh-2003a" NAME="Chuh 2003a" TYPE="JOURNAL_ARTICLE">
<AU>Chuh A, Lee A, Molinari N</AU>
<TI>Case clustering in pityriasis rosea - a multi-center epidemiological study in primary care settings in Hong Kong</TI>
<SO>Archives of Dermatology</SO>
<YR>2003</YR>
<VL>139</VL>
<PG>489-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuh-2003b" NAME="Chuh 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Chuh AAT</AU>
<TI>Diagnostic criteria for pityriasis rosea - a prospective case control study for assessment of validity</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>101-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuh-2003c" NAME="Chuh 2003c" TYPE="JOURNAL_ARTICLE">
<AU>Chuh AAT</AU>
<TI>Quality of life in children with pityriasis rosea - a prospective case control study</TI>
<SO>Pediatric Dermatology</SO>
<YR>2003</YR>
<VL>20</VL>
<PG>474-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuh-2003d" NAME="Chuh 2003d" TYPE="JOURNAL_ARTICLE">
<AU>Chuh AAT</AU>
<TI>A prospective case control study of autoimmune markers in patients with pityriasis rosea</TI>
<SO>Clinical and Experimental Dermatology</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>449-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuh-2005a" NAME="Chuh 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Chuh AAT, Chan HHL</AU>
<TI>The effect on quality of life in patients with pityriasis rosea - is it associated with rash severity?</TI>
<SO>International Journal of Dermatology</SO>
<YR>2005</YR>
<VL>44</VL>
<PG>372-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuh-2005b" NAME="Chuh 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Chuh A, Zawar V, Lee A</AU>
<TI>Atypical presentations of pityriasis rosea - case presentations</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>120-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuh-2005c" NAME="Chuh 2005c" TYPE="JOURNAL_ARTICLE">
<AU>Chuh A, Molinari N, Sciallis G, Harman M, Akdeniz S, Nanda A.</AU>
<TI>Temporal case clustering in pityriasis rosea - a regression analysis on 1379 patients in Minnesota, Kuwait and Diyarbakyr, Turkey</TI>
<SO>Archives of Dermatology</SO>
<YR>2005</YR>
<VL>141</VL>
<PG>767-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chuh-2006" NAME="Chuh 2006" TYPE="JOURNAL_ARTICLE">
<AU>Chuh A</AU>
<TI>The detection of human herpesvirus 8 DNA in plasma and peripheral blood mononuclear cells in adult patients with pityriasis rosea</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2006</YR>
<VL>20</VL>
<PG>667-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Souza-1984" NAME="de Souza 1984" TYPE="JOURNAL_ARTICLE">
<AU>de Souza Sittart JA, Tayah M, Soares Z</AU>
<TI>Incidence of pityriasis rosea of Gilbert in the Dermatology service of the Hospital do Servidor Publico in the state of Sao Paulo</TI>
<SO>Medicina Cutanea Ibero-latino-americana</SO>
<YR>1984</YR>
<VL>12</VL>
<PG>336-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drago-1997a" NAME="Drago 1997a" TYPE="JOURNAL_ARTICLE">
<AU>Drago F, Ranieri E, Malaguti F et al</AU>
<TI>Human herpesvirus 7 in pityriasis rosea</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>1367-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drago-1997b" NAME="Drago 1997b" TYPE="JOURNAL_ARTICLE">
<AU>Drago F, Ranieri E, Malaguti F, Battifoglio ML</AU>
<TI>Human herpesvirus 7 in patients with pityriasis rosea. Electron microscopy investigations and polymerase chain reaction in mononuclear cells, plasma and skin</TI>
<SO>Dermatology</SO>
<YR>1997</YR>
<VL>195</VL>
<PG>374-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harman-1998" NAME="Harman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Harman M, Aytekin S, Akdeniz S, Inaloz HS</AU>
<TI>An epidemiological study of pityriasis rosea in the Eastern Anatolia</TI>
<SO>European Journal of Epidemiology</SO>
<YR>1998</YR>
<VL>14</VL>
<PG>495-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacyk-1980" NAME="Jacyk 1980" TYPE="JOURNAL_ARTICLE">
<AU>Jacyk WK</AU>
<TI>Pityriasis rosea in Nigerians</TI>
<SO>International Journal of Dermatology</SO>
<YR>1980</YR>
<VL>19</VL>
<PG>397-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Assessing the quality of controlled clinical trials</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karabulut-2002" NAME="Karabulut 2002" TYPE="JOURNAL_ARTICLE">
<AU>Karabulut AA, Kocak M, Yilmaz N, Eksioglu M</AU>
<TI>Detection of human herpesvirus 7 in pityriasis rosea by nested PCR</TI>
<SO>International Journal of Dermatology</SO>
<YR>2002</YR>
<VL>41</VL>
<PG>563-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kempf-1999" NAME="Kempf 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kempf W, Adams V, Kleinhans M et al</AU>
<TI>Pityriasis rosea is not associated with human herpesvirus 7</TI>
<SO>Archives in Dermatology</SO>
<YR>1999</YR>
<VL>35</VL>
<PG>1070-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klauder-1924" NAME="Klauder 1924" TYPE="JOURNAL_ARTICLE">
<AU>Klauder JV</AU>
<TI>Pityriasis rosea with particular reference to its unusual manifestations</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1924</YR>
<VL>82</VL>
<PG>178-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kosuge-2000" NAME="Kosuge 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kosuge H, Tanaka-Taya K, Miyoshi H, et al</AU>
<TI>Epidemiological study of human herpesvirus-6 and human herpesvirus 7 in pityriasis rosea</TI>
<SO>British Journal of Dermatology</SO>
<YR>2000</YR>
<VL>143</VL>
<PG>795-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Labro-1998" NAME="Labro 1998" TYPE="JOURNAL_ARTICLE">
<AU>Labro MT</AU>
<TI>Anti-inflammatory activity of macrolides: a new therapeutic potential?</TI>
<SO>Journal of Antimicrobials and Chemotherapy</SO>
<YR>1998</YR>
<VL>41 Suppl B</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leonforte-1981" NAME="Leonforte 1981" TYPE="JOURNAL_ARTICLE">
<AU>Leonforte JF</AU>
<TI>Pityriasis rosea: exacerbation with corticosteroid treatment</TI>
<SO>Dermatologica</SO>
<YR>1981</YR>
<VL>163</VL>
<PG>480-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Messenger-1982" NAME="Messenger 1982" TYPE="JOURNAL_ARTICLE">
<AU>Messenger AG, Knox EG, Summerly R et al</AU>
<TI>Case clustering in pityriasis rosea: support for role of an infective agent</TI>
<SO>British Medical Journal (Clinical Research Edition)</SO>
<YR>1982</YR>
<VL>284</VL>
<PG>371-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nanda-1999" NAME="Nanda 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nanda A, Al-Hasawi F, Alsaleh QA</AU>
<TI>A prospective survey of pediatric dermatology clinic patients in Kuwait: an analysis of 10,000 cases</TI>
<SO>Pediatric Dermatology</SO>
<YR>1999</YR>
<VL>16</VL>
<PG>6-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2000" NAME="Nelson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Nelson JSN, Stone MS</AU>
<TI>Update on selected viral exanthems</TI>
<SO>Current Opinions in Pediatrics</SO>
<YR>2000</YR>
<VL>12</VL>
<PG>359-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Offidani-2000" NAME="Offidani 2000" TYPE="JOURNAL_ARTICLE">
<AU>Offidani A, Pritelli E, Simonetti O, et al</AU>
<TI>Pityriasis rosea associated with herpesvirus 7 DNA</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>313-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olumide-1987" NAME="Olumide 1987" TYPE="JOURNAL_ARTICLE">
<AU>Olumide Y</AU>
<TI>Pityriasis rosea in Lagos</TI>
<SO>International Journal of Dermatology</SO>
<YR>1987</YR>
<VL>26</VL>
<PG>234-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pariser-1987" NAME="Pariser 1987" TYPE="JOURNAL_ARTICLE">
<AU>Pariser RJ, Pariser DM</AU>
<TI>Primary care physicians' errors in handling cutaneous disorders</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1987</YR>
<VL>17</VL>
<PG>239-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Percival-1932" NAME="Percival 1932" TYPE="JOURNAL_ARTICLE">
<AU>Percival 1932</AU>
<TI>Pityriasis rosea</TI>
<SO>British Journal of Dermatology</SO>
<YR>1932</YR>
<VL>44</VL>
<PG>241-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ricci-2003" NAME="Ricci 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ricci G, Patrizi A, Neri I, Specchia F, Tosti G, Masi M</AU>
<TI>Gianotti-Crosti syndrome and allergic background</TI>
<SO>Acta Dermato-Venereologica</SO>
<YR>2003</YR>
<VL>83</VL>
<PG>202-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sato-1975" MODIFIED="2008-08-06 10:06:46 +0100" MODIFIED_BY="[Empty name]" NAME="Sato 1975" TYPE="JOURNAL_ARTICLE">
<AU>Sato M, Matsuyama R, Miyata M</AU>
<TI>Clinical studies on OE-7 chiefly in the treatment of acute respiratory infections</TI>
<SO>Japanese Journal of Antibiotics</SO>
<YR>1975</YR>
<VL>28</VL>
<PG>758-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tay-1999" NAME="Tay 1999" TYPE="JOURNAL_ARTICLE">
<AU>Tay YK, Goh CL</AU>
<TI>One-year review of pityriasis rosea at the National Skin Centre, Singapore</TI>
<SO>Annals of the Academy of Medicine of Singapore</SO>
<YR>1999</YR>
<VL>28</VL>
<PG>829-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Truhan-1984" NAME="Truhan 1984" TYPE="JOURNAL_ARTICLE">
<AU>Truhan AP</AU>
<TI>Pityriasis rosea</TI>
<SO>American Family Physician</SO>
<YR>1984</YR>
<VL>29</VL>
<PG>193-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vag-2003" NAME="Vag 2003" TYPE="JOURNAL_ARTICLE">
<AU>Vag T, Sonkoly E, Kemeny B, et al</AU>
<TI>Pityriasis rosea</TI>
<SO>Orvosi hetilap</SO>
<YR>2003</YR>
<VL>144</VL>
<PG>1623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vag-2004" NAME="Vag 2004" TYPE="JOURNAL_ARTICLE">
<AU>Vag T, Sonkoly E, Karpati S, Kemeny B, Ongradi J</AU>
<TI>Avidity of antibodies to human herpesvirus 7 suggested primary infection in young adults with pityriasis rosea</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2004</YR>
<VL>18</VL>
<PG>738-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vollum-1973" NAME="Vollum 1973" TYPE="JOURNAL_ARTICLE">
<AU>Vollum DI</AU>
<TI>Pityriasis rosea in the African</TI>
<SO>Transactions of the St. John's Hospital Dermatological Society</SO>
<YR>1973</YR>
<VL>59</VL>
<PG>269-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watanabe-1999" NAME="Watanabe 1999" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe T, Sugaya M, Nakamura K, Tamaki K</AU>
<TI>Human herpesvirus 7 and pityriasis rosea</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>1999</YR>
<VL>113</VL>
<PG>288-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watanabe-2002" NAME="Watanabe 2002" TYPE="JOURNAL_ARTICLE">
<AU>Watanabe T, Kawamura T, Jacob SE et al</AU>
<TI>Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2002</YR>
<VL>119</VL>
<PG>793-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-2001" NAME="Wong 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wong WR, Tsai CY, Shih SR, Chan HL</AU>
<TI>Association of pityriasis rosea with human herpesvirus-6 and human herpesvirus-7 in Taipei</TI>
<SO>Journal of the Formosan Medical Association</SO>
<YR>2001</YR>
<VL>100</VL>
<PG>478-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yasukawa-1999" NAME="Yasukawa 1999" TYPE="JOURNAL_ARTICLE">
<AU>Yasukawa M, Sada E, Machino H, Fugita S</AU>
<TI>Reactivation of human herpesvirus 6 in pityriasis rosea</TI>
<SO>British Journal of Dermatology</SO>
<YR>1999</YR>
<VL>140</VL>
<PG>169-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yildirim-2004" NAME="Yildirim 2004" TYPE="JOURNAL_ARTICLE">
<AU>Yildirim M, Aridogan BC, Baysal V, Inaloz HS</AU>
<TI>The role of human herpes virus 6 and 7 in the pathogenesis of pityriasis rosea</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2004</YR>
<VL>58</VL>
<PG>119-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoshida-1999" NAME="Yoshida 1999" TYPE="JOURNAL_ARTICLE">
<AU>Yoshida M</AU>
<TI>Detection of human herpesvirus 7 in patients with pityriasis rosea and healthy individuals</TI>
<SO>Dermatology</SO>
<YR>1999</YR>
<VL>199</VL>
<PG>197</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-1999" NAME="Zhang 1999" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y</AU>
<TI>Selective activity of various antiviral compounds against HHV-7 infection</TI>
<SO>Antiviral Research</SO>
<YR>1999</YR>
<VL>43</VL>
<PG>23-35</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-08-06 09:51:06 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-06 09:51:06 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Lazaro_x002d_Medina-1996">
<CHAR_METHODS>
<P>Parallel group <BR/>Duration of trial: 12 weeks<BR/>Interval of assessment: Day 3, then weekly for 4 weeks, then every 4 weeks until week 12<BR/>Unit of randomisation: Whole person<BR/>Unit of analysis: Whole person</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion Criteria<BR/>a) diagnostic<BR/>Clinical diagnosis of pityriasis rosea<BR/>b) severity of condition<BR/>Not stated<BR/>c) duration of condition<BR/>Not stated<BR/>d) other<BR/>Man or woman of any age, no history of oral steroids, antihistamine, or combination of the two within the week prior to consultation, no history of topical steroid use during the week prior to consult, negative potassium hydroxide smear on skin scrapings</P>
<P>Exclusion criteria<BR/>Participant with a history of intake of oral steroids, antihistamine or combination of the two within the week prior to consult, history of topical steroid use a week prior to consult, positive KOH, no consent for biopsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention 1: Dexchlorpheniramine Tablet 4 mg 2 times per day for 2 weeks, then once a day for another 2 weeks<BR/>Intervention 2: Betamethasone Tablet 500 mcg, 2 times per day for 2 weeks, then once a day for another 2 weeks<BR/>Intervention 3: Betamethasone 250 mcg + dexchlorpheniramine 2 mg, tablets 2 times per day for 2 weeks, then once a day for another 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome measures <BR/>ii) The proportion of participants with resolution of itch, as rated by the participant.</P>
<P>Secondary outcome measures <BR/>iv) The proportion of participants with good or excellent rash improvement as rated by a medical practitioner (reported as increase or decrease in the number of lesions).<BR/>vi) Serious adverse events, i.e. serious enough to require withdrawal of the treatment.<BR/>vii) Minor participant-reported adverse events not requiring withdrawal of the treatment.</P>
<P>Others<BR/>1. The proportion of participants with hypopigmentation and hyperpigmentation (assessed by the investigators).<BR/>2. The proportion of participants with recurrence (assessed by whom not stated).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-06 09:49:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Villarama">
<CHAR_METHODS>
<P>Parallel group <BR/>Duration of trial: 6 weeks <BR/>Interval of assessment: weekly<BR/>Unit of randomisation: whole person<BR/>Unit of analysis: whole person</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-06 09:49:54 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria<BR/>a) diagnostic<BR/>Clinical diagnosis. Based on (1) history of acute onset of skin lesions, (2) characteristic morphology of plaques including collarette scaling and erythema, (3) characteristic distribution<BR/>b) severity of condition<BR/>Not stated<BR/>c) duration of condition<BR/>Not stated</P>
<P>Exclusion criteria<BR/>Past history of signs/symptoms of other skin disorders such as psoriasis, leprosy, pityriasis lichenoides chronica, cutaneous drug reactions, syphilis, fungal infections or contact dermatitis. Oral or intravenous medications 1 week prior to consultation. Topical Corticosteroids applied at anytime during the condition. History of hypersensitivity to erythromycin, gastrointestinal ulcers, or hepatic disease Atypical variants of pityriasis rosea (localised pityriasis rosea, inverse pityriasis rosea, papular pityriasis rosea). Pregnant/lactating women. Children less than 12 years of age (due to unavailable placebo in syrup preparation).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention 1. Erythromycin (as erythromycin stearate) Capsule 250 mg, 1 capsule orally every 6 hours for 2 weeks</P>
<P>Intervention 2<BR/>Placebo (flour) Capsule (physical appearance, weight and external packaging identical as Intervention 1). 1 capsule orally every 6 hours for 2 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome measures<BR/>iii) Reduction in itch (assessed by participants using visual analogue scale).</P>
<P>Secondary outcome measures<BR/>iv) The proportion of participants with good or excellent rash improvement as rated by a medical practitioner.<BR/>vi) Serious adverse events, i.e. serious enough to require withdrawal of the treatment.<BR/>vii) Minor participant-reported adverse events not requiring withdrawal of the treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-06 09:51:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-1992">
<CHAR_METHODS MODIFIED="2008-08-06 09:50:38 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel group<BR/>Duration of trial: 20 days<BR/>Interval of assessment: Daily (not explicitly stated; implied based on report of results)<BR/>Unit of randomisation: Whole person<BR/>Unit of analysis: Whole person<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Inclusion criteria<BR/>a) diagnostic<BR/>Not stated<BR/>b) severity of condition<BR/>Not stated<BR/>c) duration of condition<BR/>Not stated</P>
<P>Exclusion criteria<BR/>Not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-06 09:51:06 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention 1: Glycyrrhizin Intravenous solution 80 ml glycyrrhizin + 500 ml 10% glucose solution once daily for 10 times = one treatment cycle</P>
<P>Intervention 2: Procaine Intravenous solution 300-600 mg procaine + 500 ml 10% glucose solution once daily for 10 times = one treatment cycle<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Secondary outcome measure<BR/>iv) The proportion of participants with good or excellent rash improvement as rated by a medical practitioner (reported as disappearance of symptoms and rash)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Arndt-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>According to the report, "Treatments were given to the right side of the body only; the left side was draped and shielded" (paragraph 3, page 381). There is no randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no mention of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grobe-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no mention of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gutowski-1950">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no mention of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalbarczyk-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no mention of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Karpouzis-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no mention of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leenutaphong-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>According to the report, "UVB irradiation was given to the right side of the body only; the left side was draped and shielded. Later, 1J of UVA irradiation was given to the left side as a placebo." (paragraph 2, page 997). There is no randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Merchant-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>According to the report, "Sixty-six patients presented to the Madigan Army Medical Center Dermatology Clinic with pityriasis rosea were treated with ultraviolet light. One-half of their anterior and one-half of their posterior trunk was treated with ultraviolet light. The other half was used as an untreated control." There is no mention of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roxas">
<CHAR_REASON_FOR_EXCLUSION>
<P>According to the report, 36 patients were alternatively assigned to study and control groups. This is pseudo-randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salin-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no mention of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sharma-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>According to the report, "Patients were allocated by alternate assignment to either the treatment or the placebo group" (paragraph 2, page 242). This is pseudo-randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Valkova-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>According to the report, "The irradiation sessions were held in a conventional UV cabin (Waldmann 7001K). Two groups of patients were formed. The first one comprised 24 (23.8%) people. The initial dose of the irradiation was 80% minimal erythema dose (MED). It was increased according to the degree of the preceding erythema. Only the right half of the body was irradiated with UVB. UVA (1 J/cm2) was given as a placebo to the left half of the body. The second group consisted of 77 (76.2%) patients. The UVB irradiation was applied to the whole body. The initial UVB dose was determined according to the phototype." There is no mention of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yamashita-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>There is no mention of randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lazaro_x002d_Medina-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Villarama">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhu-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-08-06 09:58:18 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-08-06 09:58:18 +0100" MODIFIED_BY="[Empty name]" NO="1" NOTES="&lt;p&gt;Data in this table best moved to Riask of bias tables for each included study? - author to check.&lt;/p&gt;" NOTES_MODIFIED="2008-08-06 09:58:18 +0100" NOTES_MODIFIED_BY="[Empty name]">
<TITLE>Quality components</TITLE>
<TABLE COLS="10" ROWS="4">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Randomisation sequence</P>
</TH>
<TH>
<P>Allocation concealment</P>
</TH>
<TH>
<P>Blinding</P>
</TH>
<TH>
<P>Loss to follow-up</P>
</TH>
<TH>
<P>Diagnosis certainty</P>
</TH>
<TH>
<P>Drug-induced PR</P>
</TH>
<TH>
<P>Baseline assessment</P>
</TH>
<TH>
<P>Aims, interventions clear</P>
</TH>
<TH>
<P>Use of previous medication</P>
</TH>
</TR>
<TR>
<TD>
<P>Lazaro-Medina</P>
</TD>
<TD>
<P>Adequate: randomised table provided by statistician</P>
</TD>
<TD>
<P>Unclear: method not specified</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Data is adequate. Two (7%), two (6%), and 10 (37%) patients were lost to follow up at week 4 in the three arms in the study. No reason was given by the trialists for the large number of patients who dropped out in the third arm. Patients lost to follow up were not included in the final analysis</P>
</TD>
<TD>
<P>Adequate: diagnoses made clinically supplemented by skin scraping for potassium hydroxide smear examination and punch biopsy for histopathology. The diagnoses were made in a dermatology department. The participants were classified as having typical/classical PR or variants of PR and all were included in the trial.</P>
</TD>
<TD>
<P>Drug-induced PR not specifically excluded.</P>
</TD>
<TD>
<P>Adequate: baseline assessments of participants for age, sex, duration of PR, distribution and extent of eruption of PR, presence or absence of itch all documented.</P>
</TD>
<TD>
<P>Objectives and outcome measures clearly defined. Intervention and outcome measures clearly defined.</P>
</TD>
<TD>
<P>Use of previous medications after the appearance of rash partly documented. Participants with history of taking oral corticosteroids, oral antihistamines, or applying topical corticosteroids one week before consulted were excluded. The use of other medications was not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Villarama</P>
</TD>
<TD>
<P>Adequate: computer-generated table of random numbers</P>
</TD>
<TD>
<P>Adequate: separate trialists recorded participant assignments, labelled the study drugs, and dispensed the test medications</P>
</TD>
<TD>
<P>Adequate: a flow chart indicates that the trialists and participants were blinded when assessing resolution of rash and itch improvement.</P>
</TD>
<TD>
<P>Data is adequate. Three (15%) and three (15%) patients were lost to follow up in the arms of the study. Patients lost to follow up were included in the final analysis.</P>
</TD>
<TD>
<P>Adequate: diagnoses made clinically, with application of clear clinical diagnosis criteria. No investigation was mentioned. The diagnoses were made in a dermatology department. Participants with atypical variants of PR were excluded.</P>
</TD>
<TD>
<P>Drug-induced PR not specifically excluded.</P>
</TD>
<TD>
<P>Adequate: baseline assessments of participants for age, sex, duration of PR, distribution and extent of eruption of PR, presence or absence of itch all documented. Severity of tech was documented with a visual analogue scale.</P>
</TD>
<TD>
<P>Objectives and outcome measures clearly defined. Intervention and outcome measures clearly defined.</P>
</TD>
<TD>
<P>Use of previous medications after the appearance of rash partly documented. Participants having taken oral or intravenous medications one week before consultation or who had applied topical corticosteroids at any time were excluded. The use of other topical medications was not reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhu (Abstract only, full text not available)</P>
</TD>
<TD>
<P>Unclear (Abstract only, full text not available)</P>
</TD>
<TD>
<P>Unclear (Abstract only, full text not available)</P>
</TD>
<TD>
<P>Unclear (Abstract only, full text not available)</P>
</TD>
<TD>
<P>Data is adequate. No participant was lost to follow up in the both arms in the study. (Abstract only, full text not available)</P>
</TD>
<TD>
<P>Adequate: although the method of diagnosis was not explicitly mentioned, the diagnoses were made in a dermatology department. No differentiation was made between typical and atypical PR. (Abstract only, full text not available)</P>
</TD>
<TD>
<P>Drug-induced PR not specifically excluded. (Abstract only, full text not available)</P>
</TD>
<TD>
<P>Adequate: baseline assessments of participants for age, sex, duration of PR, distribution and extent of eruption of PR documented. Presence or severity of itch at baseline not documented. (Abstract only, full text not available)</P>
</TD>
<TD>
<P>Unclear: disappearance of symptoms and rash were assessed together. Symptoms were not specified as itch. The intervention is not clearly defined. The drug doses were clearly defined. However, whilst the trialists defined treatment given for ten times (ten daily intravenous treatments) as one treatment cycle, the first group of participants received 5 to 11 days of treatment (glycyrrhizin and glucose) and the second group of participants received 10 to 20 days of treatment (procaine and glucose). The report did not state how the number of days of treatment was decided. (Abstract only, full text not available)<BR/>
</P>
</TD>
<TD>
<P>Use of previous medications after the appearance of rash not documented. (Abstract only, full text not available)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-24 14:06:54 +0100" MODIFIED_BY="Cathy Bennett">
<COMPARISON ID="CMP-001" MODIFIED="2008-07-24 14:06:43 +0100" MODIFIED_BY="Cathy Bennett" NO="1">
<NAME>Glycyrrhizin vs Procaine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-07-24 14:06:43 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>Good or excellent rash improvement as rated by a medical practitioner (disappearance of symptoms and rash)</NAME>
<GROUP_LABEL_1>Glycyrrhizin</GROUP_LABEL_1>
<GROUP_LABEL_2>Procaine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours procaine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours glycyrhizin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9830010484488934" CI_START="0.9292552389642057" EFFECT_SIZE="1.3574660633484164" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.29732294382479263" LOG_CI_START="-0.031864981755689074" LOG_EFFECT_SIZE="0.13272898103455175" ORDER="18774" O_E="0.0" SE="0.19336661699248694" STUDY_ID="STD-Zhu-1992" TOTAL_1="12" TOTAL_2="11" VAR="0.03739064856711914" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-07-24 14:06:47 +0100" MODIFIED_BY="Cathy Bennett" NO="2">
<NAME>Erythromycin vs Placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2008-07-24 14:06:47 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean reduction in itch score</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours erythromycin</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.526364295149928" CI_START="3.3736357048500727" EFFECT_SIZE="3.95" ESTIMABLE="YES" MEAN_1="5.71" MEAN_2="1.76" ORDER="18775" SD_1="0.7" SD_2="0.99" SE="0.29406881947638597" STUDY_ID="STD-Villarama" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-07-24 14:06:47 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Excellent rash improvement (cure) as rated by the medical practitioner at 2 weeks</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours erythromycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="88.64058050718594" CI_START="1.906575961405165" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="1.9476325915883486" LOG_CI_START="0.280254113025325" LOG_EFFECT_SIZE="1.1139433523068367" ORDER="18776" O_E="0.0" SE="0.9794263719645022" STUDY_ID="STD-Villarama" TOTAL_1="17" TOTAL_2="17" VAR="0.9592760180995474" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-07-24 14:06:47 +0100" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Minor adverse events (gastrointestinal upset and nausea)</NAME>
<GROUP_LABEL_1>Erythromycin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours erythromycin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.03629866378495" CI_START="0.19963767096514132" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3018174967181666" LOG_CI_START="-0.6997575053902041" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="18777" O_E="0.0" SE="1.1757350641945108" STUDY_ID="STD-Villarama" TOTAL_1="17" TOTAL_2="17" VAR="1.3823529411764706" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-07-24 14:06:49 +0100" MODIFIED_BY="Cathy Bennett" NO="3">
<NAME>Dexchlorpheniramine vs Betamethasone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-07-24 14:06:49 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Number of participants with resolution of itch, as reported by participant</NAME>
<GROUP_LABEL_1>Dexchlorpheniramine</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours betameth</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dexchlor</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6293769455635032" CI_START="0.509828031554133" EFFECT_SIZE="0.9114285714285715" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.2120215670836288" LOG_CI_START="-0.29257628966981775" LOG_EFFECT_SIZE="-0.040277361293094484" ORDER="18778" O_E="0.0" SE="0.2964032788566494" STUDY_ID="STD-Lazaro_x002d_Medina-1996" TOTAL_1="25" TOTAL_2="29" VAR="0.08785490371697267" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-07-24 14:06:49 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Number of participants with good or excellent rash improvement as rated by a medical practitioner</NAME>
<GROUP_LABEL_1>Dexchlorpheniramine</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours betameth</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dexchlor</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.056072754855693" CI_START="0.41605049445364556" EFFECT_SIZE="0.6628571428571428" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" LOG_CI_END="0.023693838599255928" LOG_CI_START="-0.3808539575180079" LOG_EFFECT_SIZE="-0.178580059459376" ORDER="18779" O_E="0.0" SE="0.23763337798316816" STUDY_ID="STD-Lazaro_x002d_Medina-1996" TOTAL_1="25" TOTAL_2="29" VAR="0.05646962233169127" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-07-24 14:06:51 +0100" MODIFIED_BY="Cathy Bennett" NO="4">
<NAME>Betamethasone vs Betamethasone + Dexchlorpheniramine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-07-24 14:06:51 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Number of participants with resolution of itch, as reported by participant</NAME>
<GROUP_LABEL_1>Betamethasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Betameth+dexchlor</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours betameth+dex</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours betameth</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.637596974257621" CI_START="0.5077686365566986" EFFECT_SIZE="0.9118773946360154" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.21420702722135643" LOG_CI_START="-0.29433412778489443" LOG_EFFECT_SIZE="-0.04006355028176899" ORDER="18780" O_E="0.0" SE="0.29871959176998786" STUDY_ID="STD-Lazaro_x002d_Medina-1996" TOTAL_1="29" TOTAL_2="17" VAR="0.08923339450722818" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-07-24 14:06:51 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="29" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Number of participants with good or excellent rash improvement as rated by a medical practitioner</NAME>
<GROUP_LABEL_1>Betamethasone</GROUP_LABEL_1>
<GROUP_LABEL_2>Betameth+dexchlor</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours betameth+dex</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours betameth</GRAPH_LABEL_2>
<DICH_DATA CI_END="83.52181472958192" CI_START="1.814431238889306" EFFECT_SIZE="12.310344827586206" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="1" LOG_CI_END="1.9217999219426871" LOG_CI_START="0.25874051448378693" LOG_EFFECT_SIZE="1.090270218213237" ORDER="18781" O_E="0.0" SE="0.9768893282181934" STUDY_ID="STD-Lazaro_x002d_Medina-1996" TOTAL_1="29" TOTAL_2="17" VAR="0.9543127595865932" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-07-24 14:06:54 +0100" MODIFIED_BY="Cathy Bennett" NO="5">
<NAME>Dexchlorpheniramine vs Betamethasone + Dexchlorpheniramine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-07-24 14:06:54 +0100" MODIFIED_BY="Cathy Bennett" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Number of participants with resolution of itch, as reported by participant</NAME>
<GROUP_LABEL_1>Dexchlorpheniramine</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone+Dex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours betameth+dex</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dex</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5599156164165944" CI_START="0.44280964415184987" EFFECT_SIZE="0.8311111111111111" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.19310110584431012" LOG_CI_START="-0.3537829289940371" LOG_EFFECT_SIZE="-0.0803409115748635" ORDER="18782" O_E="0.0" SE="0.3212423891836775" STUDY_ID="STD-Lazaro_x002d_Medina-1996" TOTAL_1="25" TOTAL_2="17" VAR="0.1031966726084373" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-07-24 14:06:54 +0100" MODIFIED_BY="Cathy Bennett" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="25" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Number of participants with good or excellent rash improvement as rated by the medical practitioner</NAME>
<GROUP_LABEL_1>Dexchlorpheniramine</GROUP_LABEL_1>
<GROUP_LABEL_2>Betamethasone+Dex</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours betameth+dex</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours dex</GRAPH_LABEL_2>
<DICH_DATA CI_END="57.052323037964534" CI_START="1.1670970865759782" EFFECT_SIZE="8.16" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.7562733325759563" LOG_CI_START="0.06710698493176571" LOG_EFFECT_SIZE="0.9116901587538612" ORDER="18783" O_E="0.0" SE="0.9922246741144711" STUDY_ID="STD-Lazaro_x002d_Medina-1996" TOTAL_1="25" TOTAL_2="17" VAR="0.9845098039215685" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Classical pityriasis rosea. The largest lesion is the herald patch. The other lesions are the secondary eruption. This person did not have any itch.<BR/>This figure was previously published by us in Journal of the European Academy of Dermatology and Venereology (2003; 17: 101-3), and is reproduced here with the kind permission of Ms Zoe Ellams, Permissions Co-ordinator, Blackwell Publishing.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-02" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>The urticarial variant of pityriasis rosea. The lesions were intensely itchy.<BR/>This figure was previously published by us in Journal of the European Academy of Dermatology and Venereology (2005; 19: 120-6), and is reproduced here with the kind permission of Ms Zoe Ellams, Permissions Co-ordinator, Blackwell Publishing.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-08-06 08:34:59 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-07-24 13:32:37 +0100" MODIFIED_BY="Cathy Bennett" NO="1">
<TITLE MODIFIED="2008-07-24 13:32:35 +0100" MODIFIED_BY="Cathy Bennett">Search strategy for CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-24 13:32:37 +0100" MODIFIED_BY="Cathy Bennett">
<P>#1 pityriasis and (rosea or Gibert or Vidal or circinata or marginata or maculata) in All Fields, from 1800 to 2004 in all products<BR/>#2 MeSH descriptor Pityriasis Rosea, this term only in MeSH products<BR/>#3 SR-SKIN in All Fields in all products<BR/>#4 (#1 OR #2)<BR/>#5 (#4 AND NOT #3)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-07-24 13:40:13 +0100" MODIFIED_BY="Cathy Bennett" NO="2">
<TITLE MODIFIED="2008-07-24 13:40:13 +0100" MODIFIED_BY="Cathy Bennett">Search strategy for MEDLINE</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-24 13:34:39 +0100" MODIFIED_BY="Cathy Bennett">
<P>1 randomized controlled trial.pt.<BR/>2 randomized controlled trials/<BR/>3 random allocation/<BR/>4 controlled clinical trial.pt.<BR/>5 double-blind method/<BR/>6 single-blind method/<BR/>7 or/1-6<BR/>8 Animal/ not Human/<BR/>9 7 not 8<BR/>10 clinical trial.pt.<BR/>11 exp clinical trials/<BR/>12 (clinic$ adj25 trial$).tw.<BR/>13 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).tw.<BR/>14 placebos/<BR/>15 (placebo$ or random$).tw.<BR/>16 research design/<BR/>17 (latin adj square).tw.<BR/>18 or/10-17<BR/>19 18 not 8<BR/>20 19 not 9<BR/>21 comparative study/<BR/>22 exp evaluation studies/<BR/>23 follow-up studies/<BR/>24 prospective studies/<BR/>25 (control$ or prospectiv$ or volunteer$).tw.<BR/>26 or/21-25<BR/>27 26 not 8<BR/>28 27 not (9 or 20)<BR/>29 9 or 20 or 28<BR/>30 exp pityriasis rosea/<BR/>31 pit?riasis rosea.mp.<BR/>32 (pit?riasis and Gibert).mp.<BR/>33 (pit?riasis and Vidal).mp.<BR/>34 pit?riasis circinata et marginata.mp.<BR/>35 pit?riasis maculata et circinata.mp.<BR/>36 (pit?riasis and circinata).mp.<BR/>37 (pit?riasis and marginata).mp.<BR/>38 (pityriasis and marginata).mp.<BR/>39 or/30-37<BR/>40 29 and 39</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-07-24 13:40:28 +0100" MODIFIED_BY="Cathy Bennett" NO="3">
<TITLE MODIFIED="2008-07-24 13:40:28 +0100" MODIFIED_BY="Cathy Bennett">Search strategy for EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-24 13:34:59 +0100" MODIFIED_BY="Cathy Bennett">
<P>1 clinical article/ (900479)<BR/>2 clinical study/ (55150)<BR/>3 clinical trial/ (300778)<BR/>4 controlled study/ (1746628)<BR/>5 randomized controlled trial/ (84225)<BR/>6 major clinical study/ (1262071)<BR/>7 double blind procedure/ (54009)<BR/>8 multicenter study/ (29048)<BR/>9 single blind procedure/ (4699)<BR/>10 phase 3 clinical trial/ (5937)<BR/>11 phase 4 clinical trial/ (461)<BR/>12 crossover procedure/ (14860)<BR/>13 placebo/ (81751)<BR/>14 or/1-13 (3445808)<BR/>15 clinical$.ti,ab. (1828723)<BR/>16 assign$.ti,ab. (168261)<BR/>17 blind$.ti,ab. (198224)<BR/>18 (clinic$ adj25 (study or trial)).ti,ab. (407400)<BR/>19 controlled$.ti,ab. (401222)<BR/>20 control$.ti,ab. (2469533)<BR/>21 cross?over.ti,ab. (40080)<BR/>22 factorial$.ti,ab. (20436)<BR/>23 follow?up.ti,ab. (17667)<BR/>24 placebo$.ti,ab. (153051)<BR/>25 prospectiv$.ti,ab. (290554)<BR/>26 random$.ti,ab. (516082)<BR/>27 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. (142837)<BR/>28 material.ab. (316995)<BR/>29 (versus or vs).ti,ab. (661420)<BR/>30 or/15-29 (5199366)<BR/>31 14 or 30 (7235366)<BR/>32 human/ (4565680)<BR/>33 nonhuman/ (2400078)<BR/>34 animal/ (23920)<BR/>35 animal experiment/ (1138499)<BR/>36 33 or 34 or 35 (2748132)<BR/>37 36 not 32 (2437573)<BR/>38 31 not 37 (6196624)<BR/>39 exp pityriasis rosea/ (296)<BR/>40 pit?riasis rosea.mp. (520)<BR/>41 (pit?riasis and Gibert).mp. (42)<BR/>42 (pit?riasis and Vidal).mp. (3)<BR/>43 pit?riasis circinata et marginata.mp. (1)<BR/>44 pit?riasis maculata et circinata.mp. (0)<BR/>45 (pit?riasis and circinata).mp. (9)<BR/>46 (pit?riasis and marginata).mp. (1)<BR/>47 or/39-46 (531)<BR/>48 38 and 47 (212)<BR/>49 remove duplicates from 48 (182)<BR/>50 from 49 keep 1-182 (182)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-07-24 13:40:38 +0100" MODIFIED_BY="Cathy Bennett" NO="4">
<TITLE MODIFIED="2008-07-24 13:40:38 +0100" MODIFIED_BY="Cathy Bennett">LILACS Search strategy for LILACS</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-24 13:35:11 +0100" MODIFIED_BY="Cathy Bennett">
<P>(Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled trials OR Mh random allocation OR Mh double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) [Words] AND (Mh pityriasis rosea OR Tw pityriasis rosea OR ( Tw pityriasis AND Tw Gibert) OR (Tw pityriasis and Tw vidal) OR (TW pityriasis circinata et marginata) OR (Tw pityriasis maculata et circinata) OR ( Tw pityriasis circinata) OR ( Tw pityriasis and marginata))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-07-24 13:40:53 +0100" MODIFIED_BY="Cathy Bennett" NO="5">
<TITLE MODIFIED="2008-07-24 13:40:53 +0100" MODIFIED_BY="Cathy Bennett">Search strategy for BIOSIS Preview</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-24 13:36:24 +0100" MODIFIED_BY="Cathy Bennett">
<P>1- Clinical Trial<BR/>2- Randomized controlled trial<BR/>3- Controlled clinical trial<BR/>4- Randomized controlled trials<BR/>5- Random allocation<BR/>6- Double-blind<BR/>7- Single-blind<BR/>8- Clinical study<BR/>9- Controlled study/<BR/>10- blind procedure<BR/>AND<BR/>Pityriasis rosea<BR/>Pityriasis vidal<BR/>Pityriasis circinata<BR/>Pityriasis and marginata</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2008-08-06 08:34:59 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2008-08-06 08:34:59 +0100" MODIFIED_BY="[Empty name]">Search strategy for www.controlled-trials.com</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-24 13:37:12 +0100" MODIFIED_BY="Cathy Bennett">
<P>Pityriasis rosea<BR/>Pityriasis vidal<BR/>Pityriasis circinata<BR/>Pityriasis and marginata</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2008-07-24 13:42:55 +0100" MODIFIED_BY="Cathy Bennett" NO="7">
<TITLE MODIFIED="2008-07-24 13:42:53 +0100" MODIFIED_BY="Cathy Bennett">Search strategy for adverse effects</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-24 13:42:55 +0100" MODIFIED_BY="Cathy Bennett">
<P>(Drug hypersensitivity [mh] OR Drug toxicity [mh] OR Product surveillance, postmarketing [mh] OR safety [mh] OR adverse effects [Subheading] OR chemically induced [Subheading] OR Adverse [tw] OR side effect* [tw] OR toxicity [tw] OR chemically-induced [tw] OR safety [tw]) AND (Pityriasis rosea [mh] OR Pityriasis rosea [tw] OR Pityriasis marginata [tw])</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>